Anda di halaman 1dari 49

NF_Cover_prova_uno:NF 14-10-2013 15:43 Pagina 1

®
12 (3)2013

ISSN 1827-8590

International Journal on Nutraceuticals, Functional Foods and Novel Foods from Research to Industrial Applications
2013 Volume 12 No.3

Enzyme
production

Natural
antioxidants
Nutrafoods 3_Layout 1 18/10/13 11.42 Pagina I

International Journal on Nutraceuticals, Functional Foods


and Novel Foods from Research to Industrial Applications

Editor-in-Chief Editorial Advisory Board


A. Poli, NFI-Nutrition Foundation M. J. Amiot-Carlin, Nutrition, Faculty of Medicine La Timone,
of Italy, Milan, Italy Institut National de la Recherche Agronomique (INRA), Marseille,
France
Co-editor E. Bombardelli, Indena Spa, Milan, Italy
F. Marangoni, NFI-Nutrition
Foundation of Italy, Milan, Italy J.B. Blumberg, Jean Mayer USDA Human Nutrition Research
Center on Aging, Tufts University, Boston (MA), USA
Section editor R. A. Clemens, Horn, La Mirada (CA), USA
T. Mennini, CEC Editore, Milan,
Italy M. Fontana, Soremartec Italia srl – Ferrero Group, Alba, Italy
A. Ghiselli, Italian National Institute of Research for Food
Associate Editors and Nutrition (INRAN), Rome, Italy
M.L. Colombo, Department
of Drug Science and Technology, D. J. A. Jenkins, Departments of Medicine and Nutritional
University of Turin, Turin, Italy Sciences, University of Toronto, Toronto, Canada
C. Galli, Department J. A Milner, Nutritional Science Research Group, Division Cancer
of Pharmacological Sciences, Prevention, National Cancer Institute, Rockville (MD), USA
University of Milan, Milan, Italy A. Ouwehand, DuPont Nutrition and Health, Kantvik, Finland
L. Morelli, Institute of S. Paglialunga, CEC Editore, Milan, Italy
Microbiology, Università Cattolica
del Sacro Cuore, Piacenza, Italy N. Salem, Jr., DSM Nutritional Products LLC, Columbia
(MD),USA
V. Silano, Medical School, II
University of Rome Tor Vergata, S. J. Salminen, Functional Foods Forum, Turku, Finland
Rome, Italy B. Scarpa, General Directorate of Hygiene and Safety of Foods
F. Visioli, Madrid Institute and Nutrition (DGISAN), Ministry of Health, Rome, Italy
for Advanced Studies (IMDEA), C. R. Sirtori, Department of Pharmacological Sciences - University
Madrid, Spain of Milan, Milan, Italy
J. A. Vinson, Department of Chemistry, University of Scranton,
Scranton (PA), USA
F. Yildiz, Food Engineering and Biotechnology, Middle East
Technical University, Ankara, Turkey

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.42 Pagina II

the copyright owner if other than Springer). The Springer Distribution Center GmbH
use of general descriptive names, trade names, Haberstrasse 7, 69126 Heidelberg, Germany
trademarks, etc., in this publication, even if not Tel.: +49-6221-345-4304
specificallyidentified, does not imply that these Fax: +49-6221-345-4229
names are not protected by the relevant laws and e-mail: subscriptions@springer.com
1 Aims and scope regulations. Business hours: Monday to Friday 8 a.m. to 8 p.m.
An author may self-archive an author-created ver- local time and on German public holidays
NUTRAfoods is an international, peer reviewed, sion of his/her article on his/her own website.
quarterly Journal focusing on nutraceuticals and He/she may also deposit this version on his/her Cancellations must be received by September 30
covering dietary-food supplements, herbals, func- institution’s and funder’s (funder’s designated) to take effect at the end of the same year.
tional foods and beverages and other topics in the repository at the funder’s request or as a result of a
field. Aim of NUTRAfoods is to provide information legal obligation, including his/her final version, Changes of address. Allow six weeks for all
to readers about all aspects of ingredients and provided it is not made publicly available until changes to become effective. All communications
products development, from chemistry, biochem- after 12 months of official publication. He/she should include both old and new addresses (with
istry and formulation to kinetic and safety testing. may not use the publisher’s PDF version which is postal codes) and should be accompanied by a
Specific attention will be devoted to efficacy studies, posted on www.springerlink.com for the purpose mailing label from a recent issue.
both preclinical and clinical. of self-archiving or deposit. Furthermore, the According to § 4 Sect. 3 of the German Postal
The Journal publishes original articles including author may only post his/her version provided Services Data Protection Regulations, if a subscriber’s
full-length or short scientific and technical research acknowledgement is given to the original source address changes, the German Post Office can
reports on health effects and development of food of publication and a link is inserted to the published inform the publisher of the new address even if
supplements, ingredients and finished products. article on Springer’s website. The link must be ac- the subscriber has not submitted a formal application
Reviews and monographs are generally invited; companied by the following text: “The original for mail to be forwarded. Subscribers not in agreement
letters will be accepted and published in accordance publication is available at www.springerlink.com”. with this procedure may send a written complaint
with the editorial board if topics discussed are of The author is requested to use the appropriate to Springer Customer Service Center GmbH, within
general interest to readers. The Journal also publishes DOI for the article (go to the Linking Options in 14 days of publication of this issue.
supplements containing proceedings of symposia the article, then to OpenURL and use the link
or special meetings. with the DOI). Articles disseminated via Back volumes. Prices are available on request.
Manuscripts submitted for publication must contain www.springerlink.com are indexed, abstracted and
a statement to the effect that all human studies referenced by many abstracting and information Microform editions are available from: ProQuest.
have been reviewed by the appropriate ethics services, bibliographic networks, subscription agen- Further information available at: http://www.il.pro-
committee and have therefore been performed in cies, library networks, and consortia. quest.com/umi/
accordance with the ethical standards laid down While the advice and information in this journal
in an appropriate version of the 1965 Declaration is believed to be true and accurate at the date of its
of Helsinki. It should also be stated clearly in the publication, neither the authors, the editors, nor 4 Electronic edition
text that all persons gave their informed consent the publisher can accept any legal responsibility
prior to their inclusion in the study. Details that for any errors or omissions that may be made. The An electronic edition of this journal is available at
might disclose the identity of the subjects under publisher makes no warranty, express or implied, springerlink.com
study should be omitted. Reports of animal exper- with respect to the material contained herein.
iments must state that the Principles of Laboratory Special regulations for photocopies in the USA:
Animal Care (NIH publication no. 86-23 revised Photocopies may be made for personal or in- 5 Advertising
1985) were followed as were applicable national house use beyond the limitations stipulated under
laws (e.g. the current version of the German Law Section 107 or 108 of U.S. Copyright Law, provided For Italy:
on the Protection of Animals). The Editor-in-Chief a fee is paid. All fees should be paid to the Copy- Anna Lebovich: al@ceceditore.com
reserves the right to reject manuscripts that do right Clearance Center, Inc., 222 Rosewood Drive, Silvia Pedretti: ss@ceceditore.com
not comply with the abovementioned requirements. Danvers, MA 01923, USA, Tel.:+1-978-7508400,
Authors will be held responsible for false statements Fax:+1-978-6468600, http://www.copyright.com, For France
or for failure to fulfill such requirements. stating the ISSN of the journal, the volume, and Robert De Picciotto: robertpicciotto@hotmail.com
the first and last page numbers of each article
The journal is open for publication of supple- copied. The copyright owner’s consent does not For Germany
ments and for publishing abstracts of scientific include copying for general distribution, promotion, Sigfried Fischer: s.fischer@sofw.com
meetings. new works, or resale. In these cases, specific
Conditions can be obtained from the Editor- written permission must first be obtained from For other countries
in-Chief or the publisher. the publisher. Alessandro Gallo: alessandro.gallo@springer.com
The Canada Institute for Scientific and Technical In-
2 Copyright formation (CISTI) provides a comprehensive, world-
wide document delivery service for all Springer 6 Production
Submission of a manuscript implies: that the work journals. For more information, or to place an
described has not been published before (except order for a copyright-cleared Springer document, Publishing Editor
in form of an abstract or as part of a published lec- please contact Client Assistant, Document Delivery, Patrizia Bianchi
ture, review or thesis); that it is not under consid- CISTI, Ottawa Springer-Verlag Italia Srl
eration for publication elsewhere; that its publication K1A 0S2, Canada (Tel. +1-613-9939251, Fax +1- Via Decembrio 28, 20137 Milano, Italy
has been approved by all co-authors, if any, as 613-9528243, e-mail: cisti.docdel@nrc.ca). Tel.: +39-02-54259733
well as - tacitly or explicitly-by the responsible au- Fax: +39-02-54259701
thorities at the institution where the work was e-mail: patrizia.bianchi@springer.com
carried out. 3 Subscription information
The author warrants that his/her contribution is Address for courier, express and registered mail:
original and that he/she has full power to make ISSN 1827-8590 (print edition) Springer-Verlag Italia Srl
this grant. The author signs for and accepts re- ISSN 2240-5291 (electronic edition) Via Decembrio 28, 20137 Milano, Italy
sponsibility for releasing this material on behalf
of any and all co-authors. Transfer of copyright to Subscription rates Managing Director
Springer (respective to owner if other than Springer) For information on subscription rates please con- Anna Lebovich
becomes effective if and when the article is accepted tact: CEC Editore
for publication. After submission of the Copyright Customer Service Via Primaticcio 165, 20147 Milano, Italy
Transfer Statement signed by the corresponding
author, changes of authorship or in the order of The Americas (North, South, Central America Typesetters
the authors listed will not be accepted by Springer. and the Caribbean) Ikona, Milan, Italy
The copyright covers the exclusive right and license journals-ny@springer.com
(for U.S. government employees: to the extent Outside the Americas Printer
transferable) to reproduce, publish, distribute and subscriptions@springer.com Gruppo Stampa GB Srl
archive the article in all forms and media of ex- Viale Spagna 154, 20093 Cologno Monzese (MI),
pression now known or developed in the future, Orders and inquiries Italy
including reprints, translations, photographic re- The Americas (North, South, Central America
productions, microform, electronic form (offline, and the Caribbean) Registrazione del Tribunale di Milano
online) or any other reproductions of similar Springer Journal Fulfillment N. 529/11 del 25 ottobre 2011
nature. P.O. Box 2485
All articles published in this journal are protected Secaucus, NJ 07096-2485, USA Distribution in Italy occurs according
by copyright, which covers the exclusive rights to Tel.: 800-SPRINGER (777-4643) to the Italian Law 196/2003
reproduce and distribute the article (e.g., as offprints), Tel.: +1-201-348-4033 (outside US and Canada)
as well as all translation rights. No material Fax: +1-201-348-4505 Springer is a part of
published in this journal may be reproduced pho- e-mail: journals-ny@springer.com Springer Science+Business Media
tographically or stored on microfilm, in electronic springer.com
data bases, video disks, etc., without first obtaining Outside the Americas
written permission from the publisher (respective via a bookseller or © Springer Healthcare – CEC Editore 2013
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina III

INDEX
N _ _ _ 14-10-2013 15:43 Pagina 1

® Editorial
ISSN 1827-8590

International Journal on Nutraceuticals, Functional Foods and Novel Foods from Research to Industrial Applications
2013 Volume 12 No.3
Do antioxidants really help? The endless debate 69
Andrea Poli

Enzymes
Review
production
Apple biophenol synergistic complex and its potential benefits 71
for cardiovascular health
Valentina Bortolotto, Cristiana Piangiolino

Natural
Original Research
antioxidants
Maternal nutritional status and the risk of birth defects 81
among Saudi women
Sahar A. Ibrahim, Om Alsaad Farouk Abd Al-Halim, Maysa A. Samy,
Ahmed M. Mohamadin
Bioprospecting of soybean for production of nattokinase 89
A fibrinolytic enzyme
Rohit Kapoor, Bibhu Prasad Panda
Antioxidants in combination with omega-3 fatty acids protect rat 97
neonatal cardiomyocytes against H2O2 induced oxidative stress
Katja Svennevig

Regulations
The European Union (EU) food safety system: 103
Principles, procedures, organization and scientific basis
Marco Silano, Vittorio Silano

Scientific Updates
Nanotech 111
Scientific Literature 112

News Update
Health Claims N65
Associations N67
Institutions N68
Ingredients & Products N71
News of Industry N79
Marketing N83
Congress Report N84
Exhibition Report N85
Exhibition Preview N88
Coming Events N89
Suppliers Index N90

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina IV
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 69

Nutrafoods (2013) 12:69-70


DOI 10.1007/s13749-013-0033-7

Editorial 69

Do antioxidants really help?


The endless debate
Andrea Poli

Correspondence to:
Andrea Poli
poli@nutrition-foundation.it

© Springer Healthcare – CEC Editore 2013

This issue of NutraFoods includes two papers on terrupted before the planned conclusion because
antioxidants and their potentially protective role of higher incidence of clinical outcomes as com-
toward free radical-induced damage. This is indeed pared with placebos. It must be underscored that
a very interesting field that is witnessing mixed re- these trials mostly employed lipophilic antioxi-
sults in the scientific literature. Let us try to criti- dants at high doses and that no patients at high
cally summarise the most recent evidence. oxidative stress level were selected; this is at odds
Free radicals are extremely reactive and can bind with what happened, as an example, in trials with
and damage cellular macromolecules such as pro- statins, which randomised hypercholesterolaemic
teins, sugars, fatty acids and DNA. However, some patients, or in those with anti-hypertensive drugs,
free radicals and reactive oxygen species do play which were run on hypertensive subjects. Yet, it
important roles in our body, in terms of signal is somewhat interesting to note that not only was
transduction. Therefore, eradicating free radical a positive trend not recorded, but often these trials
production (which is, by the way, impossible) resulted in effects that were the opposite to what
might not be a good idea. This is further compli- was expected.
cated by a careful analysis of the literature on an- How to move forward? One option (which several
tioxidants and clinical endpoints. The vast ma- authors strongly support) is to reject the notion
jority of epidemiological studies do correlate that antioxidants can ameliorate our life by reduc-
increased intakes and elevated plasma concentra- ing the incidence of degenerative diseases. With
tions of these molecules with lower incidence of this approach we might throw the baby out with
degenerative diseases such as cancer, cardiovascu- the bathwater just because we might have em-
lar disease and neurodegeneration. All-cause mor- ployed wrong approaches and, therefore, obtained
tality is also negatively correlated with antioxidant disappointing results. What about polyphenols
intake. On the other hand, controlled clinical tri- and, in general, natural antioxidants? Indeed, they
als of antioxidant molecules reached different con- might prove useful if (1) we consider in vitro and
clusions. In particular, trials with vitamin E and epidemiological trials only as starting points for
beta-carotene or their combinations (often randomised clinical trials; (2) we carefully use the
blended with vitamin C and selenium) yielded word “natural”, noting that chemistry is indispen-
negative results. Indeed, some trials have been in- sable and that natural beta-carotene is indistin-

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 70

70 Nutrafoods (2013) 12:69-70

guishable from natural beta-carotene; and (3) we take place on the low-density lipid surface, where
test mixtures of different antioxidants and select polyphenols bind and might act as scavengers. In
appropriate patients whenever possible. the meantime, we should all continue to look at
Last, but not least, we need to take into account antioxidants with an open mind and keep a bal-
that, for polyphenols to work as anti-atherosclerotic anced approach to this complex field of research,
antioxidants, free radical-mediated reactions must which urgently needs evidence-based data.

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 71

Nutrafoods (2013) 12:71-79


DOI 10.1007/s13749-013-0029-3

Review 71

Apple biophenol synergistic complex


and its potential benefits for cardiovascular health
Valentina Bortolotto, Cristiana Piangiolino

Correspondence to: Keywords:


Cristiana Piangiolino apple, phloridzin, quercetin,
c.piangiolino@principium-bsi.com chlorogenic acid, CVD,
glucose metabolism,
diabetes

Received: 29 March 2013 / Accepted: 25 June 2013


© Springer Healthcare – CEC Editore 2013

Abstract commercially available extracts. Furthermore, we


Most of cardiovascular disease (CVD) events are observed in vitro the modulation of antioxidant en-
caused by risk factors that can be controlled, treated zymes like superoxide dismutase, catalase and glu-
or modified. Amongst these factors are some mod- tathione peroxidase whose activity improved by
ifiable ones, such as hypertension, tobacco use, hy- 22.14%, 31.65% and 18.41% respectively for Apple
perglycaemia and diabetes, physical inactivity, un- PCQ® compared to the control. Another in vitro
healthy diet, cholesterol/lipids, overweight and test showed a strong inhibition degree of α-amylase
obesity. Others, such as age, gender and family his- and α-glucosidase enzymes, by 74% and 92% re-
tory, cannot be changed. spectively, for Apple PCQ® compared to the control.
Recent clinical trials and epidemiological studies These results lay the foundations for a potential
show that prevention, based on lifestyle and social regulation of glucose metabolism that will be con-
change, starting with conscious and responsible firmed by clinical studies.
nutrition, aims at delaying the use of drugs in peo-
ple in high-risk categories. Introduction
Based on this concept, we investigated some func- The leading causes of death in Western countries
tional features of an active ingredient, called Se- are cardiovascular diseases (CVD) and cancer. CVD,
lectSIEVE® Apple PCQ. It is composed of purified also known as coronary heart disease (CHD), is in-
biophenols from apple, including phloridzin, duced by independent risk factors such as cigarette
quercetin and chlorogenic acid. The high antioxi- smoking, high blood pressure, elevated serum total
dant activity of Apple PCQ® has been tested by the cholesterol and low-density lipoproteins (LDL), low
ORAC, DPPH, ABTS and Folin-Ciocalteau assays serum high-density lipoproteins (HDL), diabetes
with respect to pure standard compounds and other mellitus and advancing age. Obesity, diabetes and
metabolic syndrome show a strong correlation at a
V. Bortolotto, C. Piangiolino (•)
physiologic level (insulin resistance), because of
Principium Europe srl cause–effect relationships amongst these factors
Corso Europa 60 themselves and other CVD risk factors [1].
20020 Solaro (MI), Italy
tel +39 0296799831; fax +39 96790808 Epidemiologic studies widely report that diets rich
c.piangiolino@principium-bsi.com in fruits and vegetables protect humans against de-

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 80

You need. We make.

Truffini & Reggé, founded in 1917, is a pharmaceutical company specialized in formulation,


production scale-up and manufacture of products in tablets, capsules and granulates for the dietary,
nutritional, health-food, food supplements, pharmaceutical and medical devices markets.
We produce innovative products that have often been in the vanguard of galenic development: some examples are controlled
release multilayer tablets, oral/buccal absorption tablets and modified release hard gelatin capsules. Our flexibility allows us to
work with all kind of company: from the multi-national corporations to the small enterprises. We make for them new products with
high technical and formulative quality that meets HACCP and GMP standards supported by our ISO 9001:2008, ISO 13485:2003
certified quality system and now for the first time in food supplements’ manufacture ISO 22000:2005.
Besides, sensitively to international markets, a pharmaceutical standards’ meeting process has been launched.
GMP (Good Manufacuring Practice) according to FDA (Food and Drug
Administration) standards has been achieved and certified already.

Truffini&Reggè Farmaceutici srl - Via privata Oslavia, 18 - 20134 Milan, Italy - T. +39 02 26412402 - F. +39 02 2158657 - www.truffini.it
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 81

Nutrafoods (2013) 12:81-88


10.1007/s13749-012-0066-3

Original Research 81

Maternal nutritional status and the risk


of birth defects among Saudi women
Sahar A. Ibrahim, Om Alsaad Farouk Abd Al-Halim, Maysa A. Samy, Ahmed M. Mohamadin

Correspondence to: Keywords:


Sahar A. Ibrahim birth defects,
saharhammouda@yahoo.com congenital malformations,
nutrient intake,
vitamins, minerals,
maternal nutritional status
Received: 4 October 2012 / Accepted: 5 December 2012
© Springer Healthcare – CEC Editore 2013

Abstract the first trimester. Seventy-four cases (6.3%) dropped


Background/objectives Various studies have linked vi- out for different reasons. Follow-up was done until
tamin deficiencies in early pregnancy to birth de- women delivered and the infant was examined.
fects. The objective of this study was to identify the Results The total number of children diagnosed with
relationship between the nutritional status of preg- apparent congenital malformations was 48 (43 per
nant Saudi mothers and their dietary intake and 1000). Dietary intake of energy, protein and multiple
birth defects. vitamins (B2, B6, B12, niacin and vitamin D) and
Subjects/methods A total of 1180 healthy first-trimester minerals (calcium, phosphorus, iron and magne-
pregnant Saudi females were selected from antenatal sium), was significantly lower among mothers of
clinics in 2 hospitals and 21 health-care centres dis- infants born with birth defects.
tributed all over Al-Madinah Al-Monawarah city, Conclusion This study highlights the association of
Saudi Arabia. Full history, clinical examination, an- birth defects with the deficiency of certain nutrients.
thropometry and dietary history were performed in
Introduction
Birth defects or congenital malformations (CMs) are
Sahar A. Ibrahim (•), Maysa A. Samy
Clinical Nutritional Department
structural or functional abnormalities present at
Faculty of Applied Medical Sciences birth that cause physical or mental disability. Some
Taibah University may be fatal [1]. The term serious birth defects en-
Madinah, Saudi Arabia
saharhammouda@yahoo.com compasses disorders that are life threatening or have
16 Al-Roda Street, Manial, Cairo, Egypt the potential to result in disability. Their aetiology
Om Alsaad Farouk Abd Al-Halim includes genetic disorders and partly genetic disor-
Nursing Department ders (multifactorial genetic malformations); and
Faculty of Applied Medical Sciences
Taibah University non-genetic disorders that are the consequences of
Madinah, Saudi Arabia abnormal foetal environmental factors, including
Ahmed M. Mohamadin teratogens that disturb normal growth and devel-
Chemistry for Health Sciences Department opment of the embryo or the foetus, and as yet un-
Deanery of Academic Services
Taibah University known causes [2]. The prevalence of CM in Saudi
Madinah, Saudi Arabia Arabia (KSA) was found to be 29.46/1000 live births

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 89

Nutrafoods (2013) 12:89-95


DOI 10.1007/s13749-013-0032-8

Original Research 89

Bioprospecting of soybean for production


of nattokinase
A fibrinolytic enzyme
Rohit Kapoor, Bibhu Prasad Panda

Correspondence to: Keywords:


Bibhu Prasad Panda nattokinase
bibhu_panda31@rediffmail.com soybean fermentation
thermodynamic parameters
fibrinolytic activity

Received: 11 June 2013 / Accepted 6 September 2013


© Springer Healthcare – CEC Editore 2013

Abstract Introduction
Nattokinase (NK), a fibrinolytic enzyme, is pro- Among the various functional foods, fermented foods
duced by solid-state fermentation (SSF) of soybean are attracting much interest because of their richness
(DS 9814) by Bacillus subtilis MTCC 2616 using a in fibrinolytic enzymes. Current therapy for fibri-
rotating bioreactor. Glucose, casein, K2HPO4, FeSO4 nolysis includes urokinase, tissue plasminogen acti-
and hypoxanthine were found to be the most in- vator, streptokinase and staphylokinase. But these
fluential components for maximum NK production agents are highly costly and have hemorrhage as a
as obtained from Plackett-Burman design. The op- side effect [1]. In contrast, food-derived fibrinolytic
timum values of nutrients per (100 g of solid sub- agents are devoid of these side effects and have a nu-
strate) determined by response surface methodol- tritional value as well. Food sources of fibrinolytic
ogy were glucose 2 g, casein 1 g, K2HPO4 0.30 g, enzymes include natto, tofuyo, skipjack shiokara,
FeSO4 0.01 g and hypoxanthine 1 mg. These values chungkook-jang, kimchi and fermented shrimp paste
predicted menaquinone-7 of 0.007 µg g–1 and NK [2]. Natto is a Japanese traditional fermented food
with 310±2 FU g–1 (dry weight) of fermented soy- that contains an extracellular fibrinolysin, nattoki-
bean by B. subtilis MTCC 2616 under SSF. Crude nase [3]. Nattokinase (NK) has four times greater fib-
NK was found to be stable in the range of 30–60°C, rinolytic activity than plasmin and induced t-PA
retaining 85% of its initial fibrinolytic activity. when administered orally. The safety of natto as a
Thermodynamic parameters ∆H* (deactivation en- functional food depends on the fact that dietary
thalpy) and ∆S* (deactivation entropy) for crude natto extract does not prolong bleeding time [4, 5].
NK were found to be –335 kJ mol–1 and 5.34 kJ Along with NK, natto also contains a chemoprotec-
(mol K)–1 respectively. tive agent for cancer (genistein) and a source of di-
etary fibre (gamma-polyglutamic acid) and has an-
giotensin-I converting enzyme inhibitory activity [6].
Rohit Kapoor, Bibhu Prasad Panda (•)
Microbial and Pharmaceutical Biotechnology Laboratory
Many studies have been performed by various re-
Centre for Advanced Research in Pharmaceutical Science searchers to optimise the fermentation medium for
Faculty of Pharmacy enhancing production of NK under submerged con-
Jamia Hamdard, New Delhi 110062, India
tel +919990335013 ditions [4, 7]; purifying and characterising this en-
bibhu_panda31@rediffmail.com zyme [5, 8–10], formulating NK [11] and assessing

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 12.03 Pagina 96
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 97

Nutrafoods (2013) 12:97-102


DOI 10.1007/s13749-013-0034-6

Original Research 97

Antioxidants in combination with omega-3


fatty acids protect rat neonatal cardiomyocytes
against H2O2-induced oxidative stress
Katja Svennevig

Correspondence to: Keywords:


Katja Svennevig antioxidant
katja@nutraq.com oxidative stress
carotenoids
cardiovascular disease
astaxanthin
Received: 5 June 2013 / Accepted: 12 September 2013
© Springer Healthcare – CEC Editore 2013

Abstract Conclusion These findings suggest that a combina-


Objective Oxidative stress is involved in the devel- tion of antioxidants and omega-3 fatty acids may
opment of cardiovascular injuries. The aim of the represent potential protection against oxidative
current study was to determine whether pretreat- stress.
ment with a combination of antioxidants and
omega-3 fatty acids protects rat neonatal cardiomy- Introduction
ocytes against H2O2-induced oxidative stress. Cardiovascular diseases are highly prevalent and
Methods Rat neonatal cardiomyocytes were cultured the main cause of death in Western countries. Ox-
for 2 h with either olive oil to serve as a control or idative stress has a role in the development of car-
a combination of antioxidants and omega-3 fatty diovascular injuries and may contribute to initia-
acids (astaxanthin, lutein/zeaxanthin, vitamin C, tion and development of pathological conditions
vitamin E, vitamin D and krill oil) before oxidative [1]. During ischaemia and heart failure, reactive
stress was induced by H2O2 for 24 h. Investigations oxygen species (ROS) (e.g., hydrogen peroxide
included analysis of reliable markers for oxidative [H2O2]) are produced [2]. H2O2 is highly diffusible
stress. and induces oxidative damage in lipids and in-
Results Pretreatment of rat neonatal cardiomyocytes tramembranous proteins in the cell membrane.
with a combination of antioxidants and omega-3 In recent years, the potential pharmacological ap-
fatty acids resulted in a reduction in induced lipid proach to confer cardioprotection by oral ingestion
peroxidation measured by 8-iso-prostaglandin F2al- of antioxidants and omega-3 fatty acids has been a
pha (8-iso-PGF2α) and malondialdehyde (MDA) key focus area. Mounting evidence suggests that
levels. In addition, protein oxidation was reduced oral intake of eicosapentaenoic acid (EPA) and do-
after calculating the protein carbonyl level. cosahexaenoic acid (DHA) protects against cardio-
vascular diseases [3, 4]. Concerns remain that sup-
Katja Svennevig (•)
plementation with omega-3 fatty acids may increase
NutraQ lipid peroxidation. However, it has been shown that
Enebakkveien 117 A DHA and EPA supplementation can have anti-in-
0680 Oslo, Norway
tel +47 991 52 220 flammatory and antioxidative effects [5–8].
katja@nutraq.com The ability of the antioxidants vitamin C and vita-

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 103

Nutrafoods (2013) 12:103-109


DOI 10.1007/s13749-013-0035-5

Regulations 103

The European Union (EU) food safety system


Principles, procedures, organisation and scientific basis
Marco Silano, Vittorio Silano

Correspondence to: Keywords:


Marco Silano European Union
marco.silano@iss.it food safety
legislation
risk assessment
European Food Safety Authority
Received: 17 June 2013 / Accepted: 23 September 2013
© Springer Healthcare – CEC Editore 2013

Abstract and institutional process that, over about 10 years,


The principles, procedures, organisation and sci- has substantially improved the food safety system
entific basis of the European Union food/feed safety in the European Union and has proven to be very
system have been effectively modernised by Regu- capable of coping with urgent and emergency is-
lation (EC) 178/2002 and subsequent regulations. sues. Moreover, the main results obtained by the
Reg. 178/2002 also established the European Food EFSA in its first 10 years of activity in terms of both
Safety Authority (EFSA), an independent scientific innovative methodologies and opinions on specific
agency competent for risk assessment in the issues and the complexities of the mechanisms put
food/feed chain and risk communication in the in place to ensure its independence are also ad-
European Union. Moreover, since 2002, a very in- dressed.
tensive regulatory process has been activated by
the European Commission in at least four main Introduction
sectors: (i) food/feed hygiene packaging, (ii) con- The European Union (EU) has reached its current
sumer information, (iii) intentionally added sub- status through a long-term process involving a
stances to food or feed and (iv) non-intentionally growing number of Member States.
added substances to food or feed. This paper de- • Since 25 March 1957: Belgium, Italy, Luxem-
scribes the main characters of this overall regulatory bourg, France, the Netherlands and Germany
• Since 1 January 1973: Denmark, Ireland and the
United Kingdom
Marco Silano (•) • Since 1 January 1981: Greece
Department of Food Safety and Veterinary Public Health
• Since 1 January 1986: Portugal and Spain
Istituto Superiore di Sanità
Viale Regina Elena 299 • Since 1 January1995: Austria, Finland and Sweden
00161 Rome, Italy • Since 1 May 2004: Cyprus (the Greek part), Czech
tel +39 06 49906001
marco.silano@iss.it
Republic, Estonia, Hungary, Latvia, Malta, Poland,
Slovakia and Slovenia
Vittorio Silano • Since 1 January 2007: Bulgaria, Romania
Medical School
II University of Roma Tor Vergata It is not surprising, therefore, that between 1957
Rome, Italy (when the Treaty of Rome establishing the Euro-

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 110


  springer.com

Sign up for
SpringerAlerts
The best way to keep you up-to-date
with new developments in your field!
You can customize your SpringerAlerts to deliver exactly
the information you need!

We offer
 Table of Contents Alerts for Journals
 Table of Contents Alerts for Book Series
 New Book Alert

As an alerts subscriber, you will receive


 Reliable news about journals and upcoming books
 Special offers – be the first to know about free online access
to journals and discounts on books

springer.com/alerts – fast, free and flexible

SIGN UP
TODAY

011759a
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 111

Nutrafoods (2013) 12:111


DOI 10.1007/s13749-013-0036-4

Nanotech 111

NanoSustain project
Successful completion of the EU FP7 project
Tiziana Mennini

© Springer Healthcare – CEC Editore 2013

The NanoSustain Project Coordinator, Rudolf Reuther nanotubes containing epoxy resins) or a lower inflammatory
(rudolf.reuter@enas-online.com), announced in his final response (from nano-TiO2 containing paint) than the pure nano-
newsletter of August the successful completion of the EU FP7 materials, which will limit any possible risks to human health.
NanoSustain project, after three years of intensive research work, But the extent to which the as yet unknown release of nano-
reporting and evaluation. materials from products into natural systems (water, soil) may
Although still under review by the European Commission, the give rise to indirect (environmental) exposure with possible ad-
final report was submitted in July 2013 including the second verse effects is still to be established.
periodic report with an extensive description of the analytical Based on the comprehensive data generated on human and en-
and experimental work performed and results achieved, and vironmental hazard, exposure and possible risks, NanoSustain
the final project report summarising the dissemination and ex- explored the suitability of current waste treatment technologies
ploitation of the outcome of the project and how the project to safely handle nanomaterials at the end of their product life.
has fostered current efforts on nanosafety towards a more ho- To sum up, a good level of degradability was observed and there
listic assessment of the benefits and risks associated with engi- was no ecotoxicity of paper containing nanocellulose, meaning
neered nanomaterials (EN). that this organic nanomaterial may rapidly degrade and transform
The huge amount of brand new scientific data generated during into harmless compounds when released in the environment.
the course of the project has provided new evidence and knowl- Also, incineration has been tested as a final treatment option
edge on how nanomaterials may interact and react with living for carbon nanotubes (CNT) containing epoxy resins, where
systems and how strongly their behaviour depends on the par- reuse or recycling or land-filling may not be a possible or safe
ticular physicochemical form and surface properties rather than disposal option.
on composition or concentration. The project focused on three This technology did not give rise to the release and emission of
nanoparticles (TiO2, ZnO and multiwall carbon nanotube) pro- CNT particles in the combustion gas or their deposition in the
duced worldwide in large quantities, in addition to nanocellu- resulting bottom ash but proved suitable to recover the energy
lose, a relatively new compound derived from sustainable contained in this particular nanoproduct.
sources and with an enormous potential for future applications. Melting of coated glass released nanoparticles, but the number
Overall results suggest and confirm the basic assumption that and mass concentration of emitted particles did not depend on
any human toxicity associated with nanoproperties or nanos- whether coating was applied or not, or on the type of coating,
tructures may be masked or even eliminated when free nanopar- i.e., whether nano-ZnO was added or not. In addition, leaching
ticles become embedded, bound or incorporated in the solid experiments showed that Zn2+ is released in particular at low
matrix of a product or environmental substrate. and high pH, low salinity and high DOC from both the nano-
Concerning the ecotoxicity of nanoparticles, only nano-ZnO and micro-sized ZnO-coated glass, which may be particularly
showed an acute and dose-related toxic response (against Vibrio relevant in case these products end up in land-fills.
fischeri), which corresponded well with the concentration of To obtain a more holistic view on the potential environmental
dissolved Zn2+ ions, indicating that the observed toxicity may impact of selected nanomaterials that may occur along their
be ruled by the known dissolution of divalent Zn2+ from the product chain, but also to identify new opportunities for a
solid matrix rather than by nano-ZnO. better environmental design, behaviour and sustainability at
None of the tested pure nanomaterials showed any “nanospe- an early stage, life cycle analyses (LCA) were also realised for
cific” toxicity. Dustiness tests performed to simulate routine some applications: nanocellulose applied in various types of
handling of nanomaterials showed that nanoparticles are re- paper, nano-TiO2 added to paint, nano-ZnO used in coated glass
leased from all tested products or composites irrespective of and CNT embedded in epoxy resins.
whether these products contained nanomaterials or not, and Four life-cycle phases were addressed, i.e., (1) the production of
that the generated dust revealed either no toxicity (from carbon EN, (2) production of EN-containing products, (3) their use and
(4) end-of-life recycling/disposal. The detailed results can be
seen in the project homepage (www.nanosustain.eu), which
Tiziana Mennini (✉) will remain active and provide ongoing open access to follow
Milan, Italy up the continuous publication of all results achieved within
tm@ceceditore.com the NanoSustain project.

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 112

Nutrafoods (2013) 12:112-113


DOI DOI 10.1007/s13749-013-0037-3

Scientific Literature 112

Dietary supplement– and food–drug interactions


Tiziana Mennini

© Springer Healthcare – CEC Editore 2013

With the increasing use of dietary supplements, the risk of in-


Increased risk of bleeding
teraction with drugs has become a real concern not only for
Herbal/botanical products Drug
botanicals, which are more likely to have documented drug in- Salviae miltiorrhizae (Radix) Aspirin, ticlodipine, warfarin
teractions and thus are the most studied. Some foods and nu- Angelica sinensis Aspirin, heparin, ticlodipine, warfarin
trients have also been reported to interact with drugs [1, 2], so Evening primrose Warfarin
the topic is attracting more and more interest in the literature. Ginkgo biloba Aspirin, heparin, ticlodipine, warfarin, clopidogrel,
The case of grapefruit juice is well known. It can interact with dipyridamole, ibuprofen, naproxen, cilostazol
many drugs metabolised via the cytochrome P450 enzyme Licorice Warfarin
Willow Diclofenac, ibuprofen, naproxen, ticlopidine,
CYP3A4. Meals can also interfere with levodopa metabolism,
warfarin
and food with high calcium content may reduce ciprofloxacin Vitamins/minerals/amino acids
bioavailability. Vitamin E Dicumarol
But the reverse interaction can also occur. For instance, proton Other supplements
pump inhibitors have adverse effects on key nutrients such as Glucosamine Warfarin
vitamin B12, calcium, magnesium and iron; and carbamazepine Decreased warfarin effect
might lower biotin status. Herbal/botanical products
Regarding herbs and dietary supplements, a recent exhaustive American ginseng
systematic literature review reports documented drug interac- Hypericum perforatum
tions [3] based on animal studies, human observational studies Vitamins/minerals/amino acids
and clinical trials. The severity of the documented interactions Vitamin K
was categorised according to MicroMedex (contraindicated, ma- Increased digoxin toxicity
jor, moderate, minor) and the Natural Medicines Comprehensive Herbal/botanical products
Database (NMCD) (major, moderate, minor). The definitions of Salviae miltiorrhizae (Radix)
major, moderate, and minor were similar in the two databases, Digitalis
while contraindicated interactions were classified as major in Hawthorn
NMCD. Asclepias tuberosa
Aloe vera
Among all the studies included, 166 deal with herbal/botanical
products, for a total of 890 pairs (60%) of documented interac- Increased digoxin toxicity
tions. The top five botanical products with documented drug Herbal/botanical products Drug
interactions were Hypericum perforatum, Ginkgo biloba, Piper Kava Benzodiazepines, morphine, phenobarbital,
droperidol
methysticum, Digitalis purpurea and Salix alba.
Valerian Alprazolam, phenobarbital
H. perforatum is well known to interact with the cytochrome
Increased hypotensive effects
P450 3A4 pathway and with the P-glycoprotein pathway, de-
Herbal/botanical products Drug
creasing plasma levels and the effect of many drugs like warfarin,
Mucuna pruriens Methyldopa
digoxin, cyclosporin and protease inhibitors (especially indi-
Vitamin/mineral/amino acids
navir). The Authors dedicated a separate summary table to the Arginine Enalapril, nitroglycerin
many H. perforatum–drug interactions with major severity, to Other supplements
which interested readers should refer for further details. N-acetylcysteine Nitroglycerin
In the vitamins/minerals/amino acids category, the Authors con-
Table 1 Examples of the most relevant documented dietary
sidered 28 studies, with 529 pairs (35%) of interactions. The supplement–drug interactions with major severity
top five in this group were magnesium, calcium, iron, vitamin (May cause life-threatening damage and/or serious
A and potassium. An increased risk of vitamin A toxicity has adverse effects)

been documented with acitretin, bexarotene, etretinate,


Tiziana Mennini (✉) isotretinoin and tretinoin. An increased risk of hyperkalaemia
Milan, Italy has been reported for interactions of potassium supplements
tm@ceceditore.com with potassium-sparing diuretics (amiloride, triamterene), an-

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 113

Nutrafoods (2013) 12:112-113


113

giotensin converting enzyme (ACE) inhibitors, indomethacin and, with the availability of consistent data from clinical trials,
and spironolactone. can be predicted and managed in the clinical practice. Although
The third category comprises other supplements, with 19 studies the negative effects of nutrients and supplements on drugs are
and 72 pairs (5%) of interactions: melatonin, coenzyme Q10, reported most often, both pharmacists and physicians need to
dehydroepiandrosterone (DHEA), creatine and fibre are the five also be informed of the potential negative effects of some phar-
most reported. Red yeast rice is also of interest in this category, maceuticals on the absorption, metabolism and utilisation of
reported to have a major severity interaction with cyclosporine, nutrients, and this can be of particular importance for people
causing increase of creatine phosphokinase values. Studies in undergoing long-term drug treatment, like the elderly. Further
vitro and in animal models [4] demonstrated that the polar frac- knowledge on this topic may improve patient care.
tion of red yeast rice extracts enhanced P-glycoprotein activity
and inhibited the P450 cytochromes 1A2, 2C9 and 3A4, sug- References
gesting that the risk of interaction with drugs that interplay 1. Plotnikoff GA (2011) Drug–nutrient interactions. Minn Med
with these two pathways could be reduced by removing the po- 94(10):60–62
lar fraction of red yeast rice preparations. 2. Boullata JI (2013) Drug and nutrition interactions: Not just
Table 1 summarises some of the most relevant documented di- food for thought. J Clin Pharm Ther 38:269–271
etary supplement–drug interactions reported with major severity. 3. Tsai HH, Lin HW, Simon Pickard A, Tsai HY, Mahady GB
It can be seen that the drugs that mostly contributed to docu- (2012) Evaluation of the documented drug interactions
mented interactions are warfarin, aspirin, digoxin and ticlopi- and contraindications associated with herbs and dietary
dine. Many of the observed interactions with warfarin are related supplements: A systematic literature review. Int J Clin Pract
to its metabolic route of clearance and competition for binding 66(11):1056–1078
to serum albumin. 4. Fung WT, Subramaniam G, Lee J, Loh HM, Leung PH (2012)
In conclusion, it appears that drug and nutrition interactions, Assessment of extracts from red yest rice for herb–drug in-
including dietary supplements, are becoming better recognised teraction by in vitro and in vivo assays. Sci Rep 2:298
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina 114

 springer.com

springer.com
The Innovative Website
Focused on You

Sign up for SpringerAlerts to get the latest news in your field


Save money through Springer’s Online Sales
Order with special savings – for authors, journal contributors,
society members and instructors
Find all books and journals
Download free e-sample copies of journals and book chapters

springer.com – be the first to know

VISIT
TODAY

011743a
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N65

Nutrafoods (2013) 12:N65-N66


DOI 10.1007/s13749-013-0038-2

Health Claims N65

Marketing products with health claims in the EU


Key challenges in 2013 and beyond
Stefanie Geiser

© Springer Healthcare – CEC Editore 2013

Companies are facing a range of regulatory challenges in mar- • one claim on carbohydrates and contribution to the mainte-
keting their functional food and food supplement products with nance of normal brain function, which is currently under
health claims in the European Union (EU). In addition to the discussion by the European Parliament; and
requirement to comply with national rules related to product • one claim relating to very low-calorie diets and another claim
composition, they need to face EU-wide and, if applicable na- on foods with reduced lactose content, which are pending
tional rules related to health claims and labelling. the review of the legislation on foods for Particular Nutritional
The year 2013 is a tough one for the labelling and advertising of Uses (PARNUTS).
food supplements in the EU. The transition period for the use of Most importantly, around 2000 claims for botanicals remain
most generic Article 13.1 health claims that are not authorised included on the revised Article 13.1 “finalisation pending list”
by the European Commission (EC) ended in December 2012. of the EC, since the commission still needs to decide which ap-
Most health claims for health food products must now be in proach to take for the evaluation of claims for botanicals. These
line with those authorised for use in the EU claims register. “on-hold” claims may temporarily continue to be used on na-
Companies that wish to use health claims that are not yet au- tional markets in the EU until the commission has taken a final
thorised in the EU must apply for EU approval via the submis- decision, as long as:
sion of a health claims dossier to the European Food Safety Au- • they are compliant with the general provisions of the EU
thority (EFSA), followed by an EFSA favourable opinion and Claims Framework Regulation, and
final EC approval. • they are made in line with national applicable claims rules of
the Member State authorities where products are marketed.
Status of the authorised generic (Article 13.1) Apart from health claims for botanicals and the small set of
health claims list process claims “on hold”, for which companies can follow national
In 2012, the EU adopted a list of 222 generic health claims al- rules, companies do require EU authorisation for the use of all
lowed to be made on foods (the so-called first “Article 13.1 health claims. To obtain EU approval it is now necessary to
list”). A further set of six generic health claims (Article 13.1 submit a health claims dossier to the EFSA for evaluation, fol-
claims) were authorised in June 2013. These relate to alpha-cy- lowed by the EC claims approval process.
clodextrin, prunes, fructose, docosahexaenoic acid (DHA) and In order to evaluate the chances of approval, it is therefore im-
DHA/eicosapentaenoic acid (EPA). These were included in the portant to monitor the latest EFSA trends, with regards to claims
list of authorised health claims of the EU claims register, which for which the EFSA has provided positive opinions and those
also lists other health claims that were authorised via specific with “unfavourable” outcomes.
EFSA dossier applications (Article 13.5 and 14 health claims).
The EU claims register currently includes 2200 total claim en- Latest EFSA trends for claims approvals
tries, of which 248 are authorised and 1952 are non-authorised
health claims. Authorised claims in the EU now predominantly So far in 2013, EFSA has issued a total of 22 health claims opinions,
relate to vitamins and minerals, with only around 55 health re- of which only 7 had a positive/favourable outcome. In the set of
lationships approved for claims relating to other substances. EFSA opinions published in July 2013, only two out of eight opin-
On the other hand, claims for some other substances remain ions were negative; the six positive claims opinions included:
“on hold” in the Article 13.1 process to further clarify the con- • the contribution of folic acid to the reduction of risk of neural
ditions of use. These include: tube defects, iron to normal cognitive development, magne-
• five claims on caffeine, for which the EFSA has been asked to sium to normal development of bone and vitamin A to the
provide a safety assessment before a final decision can be normal function of the immune system;
taken; • a food supplement plant-based compound combination “Lim-
icol” and the reduction of blood LDL-cholesterol concentra-
tions; and
• non-fermentable carbohydrates and maintenance of tooth
Stefanie Geiser (✉)
mineralisation.
EAS Strategic Advice (Europe office)
info@eas.eu In principle, this confirms the overall trend of past years, when
www.eas.eu the EFSA approved claims for vitamins/minerals, cholesterol re-

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N66

N66 Nutrafoods (2013) 12:N65-N66

duction and tooth health related claims in particular, while re- and understanding of the required standards will certainly pave
jecting many other ingredient/function claims, such as those the way for 2014 and beyond.
for probiotics, CoQ10 and cranberry. Nevertheless, the latest
developments could be seen overall as an upwards trend when
comparing 2013 EFSA opinion outcome numbers with those of European Advisory Services (EAS) will be participating at the Fi Eu-
2012, when only around 10% of outcomes were positive (only rope & Ni, 19–21 November 2013, Messe Frankfurt, Germany,
4 new positive opinions out of a total of 37). presenting in the free 30-minute organised seminars in the Industry
Insights Theatre. The focus will be on the latest developments on
The reasons for this slight upwards trend might be that compa-
claims, novel foods, fortified foods and foods for particular nutritional
nies are starting to have better awareness of the EFSA’s standards uses (PARNUTS) in the EU. For further information: http://www.
for applications and/or have sought advice from scientific ex- foodingredientsglobal.com/europe/learning-hub/show-features/in-
perts to assist in evaluating whether their scientific data may dustry-insight-theatre?cid=fie_ema_drv_vis_23sep2013.
meet EFSA approval criteria. To increase the chances of suc- EAS is also organising a CIS Regional Workshop in Brussels on 28
November 2013, which will give practical guidance to companies
cess—and since the EFSA standards are tough and often under-
on how to avoid the pitfalls of food supplement circulation and
estimated—companies are strongly advised to seek expert advice market regulation in the Customs Union of Russia, Belarus and
and undertake a gap-match analysis of their claims dossiers Kazakhstan. For further information, visit http://www.eas-cis.com.
against EFSA standards before submission. Increasing expertise

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N67

Nutrafoods (2013) 12:N67


DOI 10.1007/s13749-013-0039-1

Associations N67

European Federation of Associations


of Health Product Manufacturers (EHPM)
Workshop on botanicals regulation
© Springer Healthcare – CEC Editore 2013

On 27 June, a European Parliament workshop co-organised by “It is very clear that through sharing the expertise from na-
EHPM and Marc Tarabella (Belgian Member of the European tional authorities in Member States that have a long history
Parliament, MEP) brought together the various stakeholders in- of using botanicals in foods and foods supplements, the basis
volved in and subject to the regulatory rules on botanical food for workable EU system already exists. The European Com-
supplements. The workshop had over 70 participants including mission and Member States continue to reflect on the most
MEPs, Commission officials, national authorities and industry appropriate approach to take to the regulation of botanicals”
stakeholders. The workshop:
• Highlighted existing examples of botanicals regulation from Following the workshop, the host Marc Tarabella summed up
Member States. Philippe Mortier, Guillaume Cousyn and Bruno the event by saying:
Scarpa from the Belgian, French and Italian authorities, re-
spectively, participated in the discussions and shared national “My objective in organising this workshop was to highlight
experiences. These speakers also highlighted the potential of existing best practice and the fact that a system that is workable
the BELFRIT project through which Belgium, Italy and France for SMEs and provides adequate protection for consumers is
have developed a common list of botanicals and conditions possible. I hope the event has been useful for all participants”
for their use in food/food supplements.
• Illustrated the economic contribution of the botanical food EHPM would like to thank Marc Tarabella for facilitating the
supplement sector to the EU economy through a presentation debate on this topic by organising the workshop and the Com-
by EHPM Chairman Alban Maggiar. mission officials, MEPs, national authorities and industry stake-
• Provided participants with a real insight into the quality and holders that participated. EHPM’s position paper on botanicals
safety procedures applied by companies manufacturing botan- can be downloaded from the EHPM website.
ical food supplements. This was achieved through a presen-
tation from Michel Horn from the Belgian company Ortis.
• Featured a strong speech from Irish MEP Marian Harkin em-
phasising the need to create a regulatory structure for botanicals Alban Maggiar
that takes into account that most of the companies in the EHPM Chairman
tel +33 1 45 63 60 83
sector are SMEs and respects the “Think Small First” principle. a.maggiar@healthproductmanufacturers.eu
• Concluded with a panel discussion on how to combine con-
sumer protection and safety with SME-friendly regulation. Patrick Ahern
Eric Poudelet from the European Commission and French MEP EHPM Director General
tel +32 2 721 64 95
Gilles Pargneaux joined the other speakers at the workshop in
p.ahern@healthproductmanufacturers.eu
the panel.
Following the workshop, EHPM Chairman Alban Maggiar, re- www.ehpm.org
flecting on the discussions, noted that:

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N68

Nutrafoods (2013) 12:N68-N69


DOI 10.1007/s13749-013-0040-8

Institutions N68

Dietary Supplement Labeling Act


Reintroduced in the USA?

© Springer Healthcare – CEC Editore 2013

Last August, Senator Dick Durbin introduced the Dietary Sup- In January 2010, the FDA issued a warning letter to the manu-
plement Labeling Act to “improve the information available to facturer of Drank for selling a beverage containing melatonin,
consumers, and to curb the prevalence of drinks and foods that an unapproved food additive which causes drowsiness. The
are masquerading as dietary supplements as a means of avoiding manufacturer responded by changing the labelling of Drank
reviews and regulation by the FDA.” from a “beverage” to a “dietary supplement.” The FDA has not
“At most convenience stores, you can’t make it to the cash reg- yet taken action, because without a clear definition for “con-
ister without encountering flashy advertising displays for energy ventional food and beverage” it is difficult to address this kind
supplements like Rockstar Energy Drink and 5-Hour Energy. of conflict.
These products, which market themselves as dietary supplements In 2006, Durbin led a bipartisan effort to enact legislation re-
that offer a boost of energy, are foods and beverages taking ad- quiring manufacturers to report serious adverse events related
vantage of the less stringent safety standards for dietary supple- to consuming dietary supplements, enhancing the FDA’s ability
ments under current law. When consumers walk down the aisle, to identify and respond more quickly to potential health prob-
they see products that contain potentially unsafe additives right lems. The Dietary Supplement Labeling Act would build on that
next to beverages that have undergone FDA approval, but they by requiring dietary supplement manufacturers to disclose the
aren’t easily able to tell the difference,” Durbin said. known risks of ingredients and display a mandatory warning if
Unlike manufacturers of conventional food and beverage prod- the product contains a dietary ingredient that may cause po-
ucts containing additives, manufacturers of dietary supplements tentially serious adverse events. Labels would also have to in-
do not have to prove that their products are safe before selling clude the batch number, which would help the FDA identify
them to consumers. and recall contaminated product.
The legislation directs the FDA to establish a definition for “con- “People using dietary supplements have the right to know the
ventional foods,” which would clarify which products are foods potential risks. Some ingredients may be safe for the general
and should be regulated as such and which products are meant population but introduce risk for groups like children or pregnant
to be health aids and should be regulated as dietary supplements. women – or they should be avoided by people with health con-
Under current law, it is the choice of the manufacturer as to dition like diabetes or high blood pressure. In addition, some of
whether a product is classified as a food or as a dietary supple- these supplements – such as energy drinks which are heavily
ment. The distinction between dietary supplements and foods marketed to young adults – are being taken in large doses by
with dietary ingredient additives is not always clear, leaving consumers who aren’t aware of the potentially dangerous side
room for some food products to be marketed as dietary supple- effects,” Durbin said.
ments in order to circumvent the safety standards required for Durbin’s legislation would also require manufacturers to register
food additives. dietary supplement products with the FDA, and provide a de-
“My goal is to take the decision about how a product will be scription of each dietary supplement, a list of ingredients and a
regulated out of the hands of the manufacturer and put it in copy of the label. This would allow the FDA to know how many
the hands of the FDA where it belongs,” Durbin said. “Con- dietary supplements are on the market and how many products
sumers who don’t scour the fine print on the back of products contain certain ingredients, increasing their capacity to inform
may never know the difference, but they will be safer as a result manufacturers of possible safety concerns.
of this bill.” This is not the first time the FDA has been asked to clarify their
“It’s important to note most products labelled as dietary supple- authority to regulate certain dietary supplements and food ad-
ments are legitimate health aids. I take a daily vitamin just as ditives. In January 2000, the FDA issued a 10-year plan to im-
millions of Americans do. My gripe is not with the array of vita- plement the Dietary Supplement Health and Education Act of
mins available at health stores across the nation; my gripe is 1994 (DSHEA), which identified the need to clarify the distinc-
with products containing potentially dangerous additives, labelled tion between conventional foods and dietary supplements.
as ‘dietary supplements’ and marketed to young adults who find Moreover, U.S. General Accountability Office (GAO) reports in
them on store shelves right next to conventional food and bev- 11 July 2000 and 29 January 2009 recommended FDA clarify
erages whose ingredients have been deemed safe by the FDA. the boundary.
The current system favours the manufacturers of these products In response to the introduction of S. 1425, the Dietary Supple-
to the detriment of consumers – and that needs to change.” ment Labeling Act of 2013, by Senators Richard Durbin and

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N69

Nutrafoods (2013) 12:N68-N69

Richard Blumenthal, the Council for Responsible Nutrition (CRN),


the leading trade association representing the dietary supple-
Fibregum
Fibr m ™

ment industry, issued the following statement.


Statement by Steve Mister, president & CEO, CRN: “CRN appre-
ciates Sen. Durbin’s continued interest in providing consumers
with additional assurance of the safety and benefits of their di-
etary supplements. However, we oppose the Dietary Supplement
Labeling Act of 2013 because it creates added burdens for both
FDA and companies already following the law, but does not ad-
dress the problem of those companies that are disregarding the
law. Without robust enforcement, companies who look for loop-
holes and disregard their legal obligations will continue to
ignore new requirements. Rather than creating new laws, our
industry needs a renewed commitment from Congress to pro-
vide FDA with additional funding and resources so the agency
can use the ample enforcement tools already at its disposal to
take aim at companies that do not comply with the regulations
currently in place to protect consumers.
We cannot support legislation that directs FDA to require warn-
ing labels for products or ingredients that ‘could cause’ adverse
events or potential risks as this is a case of the precautionary
principle run amok. While the premise may be well intentioned,

All-natural
in practice this requirement would lead to confusing and un-
necessary label instructions likely to deter consumers from using
beneficial dietary supplements based on uncommon or minis-
cule risks. Further, a new law is unnecessary because the Dietary
Supplement Health & Education Act (DSHEA) already provides soluble fiber
FDA with the authority to mandate warning labels if the agency Food ingredients
determines there is an unreasonable risk of injury or illness un- Europe Visit us at booth
der the conditions of use provided in the labelling. Other pro- 8H17
visions of the legislation likewise create burdensome new man- Excellent source November 19-21

dates for manufacturers who are already complying with DSHEA


without addressing the industry’s outliers. of fiber
We share Sen. Durbin’s concern that consumers should be able
to expect dietary supplements are safe and beneficial, but adding Proven prebiotic benefits
new layers of bureaucratic mandates is a shotgun approach
when we need FDA to take a rifle-like aim at companies that Exceptional digestive tolerance
are putting consumers at risk.”
Low caloric value

Fibregum™ line of products is an all-natur


Fibregum al and GMO free source of
all-natural
90% soluble dietary fiber from carefully selected acacia tree gum.
Fibr egum™ is clean label and appeals to consumers because it’
Fibregum it’ss 100%
vegetable origin and available in organic gr
available ades.
grades.
Clinical studies have demonstr ated the numerous health benefits of
demonstrated
Fibr egum™ and its prebiotic properties at a daily dose of 6-15 gr
Fibregum ams.
grams.
Fibr egum™ is progressively fermented by probiotics in the intestinal tr
Fibregum act
tract
without discomfort, making it the perfect replacement for other dietary
fibers that consumers report can create gas
gas,, bloating and flatulence
flatulence..

www .nexira.com
www.nexira.com
info@nexir a.com
info@nexira.com
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N70

How Meriva® unlocks


the benefits
of curcuminoids

Curcumin, endowed with powerful


antioxidant activity, has been shown to
support joint mobility and eye health.
Unfortunately, the bioavailability
of the natural form is low.
Which is why Indena developed
Meriva®, a curcuminoid
formulation that uses the exclusive,
patented Phytosome® system
to increase bioavailability
of the natural active principles.
Meriva® improved the treadmill
walking performance of subjects by
more than 200% in just two months.
Furthermore, Meriva® showed
a significant improvement in
individuals with eye challenges.
To discover more about how
Meriva® unlocks the benefits of
curcuminoids, visit indena.com today.

Please note that the statements herein contained may be not applicable to your country. The claims made are
in reference to ingredients only, hence they do not refer to finished products and they may not comply with
Regulation EC n. 1924/2006. The marketer of any finished product containing any ingredient is responsible
for assuring that the destination of the product and the claims made for the finished product are lawful and
comply with all applicable laws and regulations of the country or countries in which the product is to be sold.
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N71

Nutrafoods (2013) 12:N71-N78


DOI 10.1007/s13749-013-0041-7

Ingredients & Products N71

UltraFer®
New delivery system for highly bioavailable iron supplements
by Alesco
© Springer Healthcare – CEC Editore 2013

The World Health Organization (WHO) has stated that iron de-
Physical and chemical properties
ficiency is the most common and widespread nutritional disor-
Appearance White to yellowish powder
der in the world. It is the only nutrient deficiency significantly Odour Characteristic
prevalent in developed countries, affecting 2 billion people Taste Characteristic
(over 30% of the world’s population is anaemic). The major Iron content (mg/g) 108–120
health consequences of iron deficiency and anaemia include
Heavy metals (ppm)
poor pregnancy outcome, lower work productivity in adults, Lead <3
impaired physical and cognitive development and reduced Mercury <0.1
school performance. Anaemia contributes to 20% of all maternal Cadmium <1
deaths; effective management of iron-deficiency anaemia (IDA)
Microbiological properties
is mandatory and since dietary changes alone are insufficient, Total viable aerobic count (cfu/g) <10,000
iron supplements are necessary. Mould/yeast (cfu/g) <100
The limitations of conventional iron supplements are reduced Enterobacteria (cfu/g) <100
absorption (10%–20% of total iron intake), metallic taste, gas- Escherichia coli absent/g
trointestinal discomfort, nausea, constipation, diarrhoea and Salmonella absent/10 g
oxidative stress. Staphylococcus aureus absent/g
To avoid constant exposure of the intestinal mucosal cells to Shelf life 2 years
unabsorbed iron excess and the consequent risk of side effects Packaging 2 plastic bags of 10 kg inside
of conventional iron supplements and, at the same time, their a cardboard box
lower effect on Hb increase, Alesco, an Italian nutraceutical sup- Storage In a dark, clean, cool and dry place
plier, developed a patented new and unique iron nanocapsules
Table 1 Analytical specifications of UltraFer®
ingredient, UltraFer®. Associating a substance with nanocapsules
markedly changes its pharmacokinetics and lowers systemic
toxicity; furthermore, the substance is prevented from early
degradation and/or oxidation reactions. 1100
1000
Composition and technical specifications 900
Iron serum levels (mg/L)

UltraFer® represents a complex of nanocapsules in which ferric 800


700
pyrophosphate mineral is protected by a phospholipid bilayer
600
membrane, mainly obtained from sunflower lecithin. Stability
500
and coating are obtained by adding other ingredients like sun- 400
flower lecithin, starch and sucrose esters of fatty acid, allowing 300
iron to be carried through the intestinal tract, where it is adsorbed, 200
providing tolerable, tasteless and highly bioavailable iron sup- 100
plementation. As UltraFer® bypasses the normal intestinal mech- 0
Control Ultrafer® Ferrous
anism of absorption, it shows an increased plasma concentration, (Carboxymethyl Sulphate
better than usual commercial oral iron compounds (Table 1). cellulose 1%)

In vivo preclinical studies Figure 1 Avc, iron serum levels (0-12 h)


An in vivo study was performed in Sprague-Dawley rats, divided
into three homogenous groups: Group 1, UltraFer®; Group 2,
ferrous sulphate; Group 3, control (carboxymethyl cellulose The results are shown in Fig. 1 and are expressed as area under
1%). To measure intestinal absorption, 0.5 mg/kg of iron was the curve (AUC). Group 1 (supplemented with UltraFer) shows
given orally to each treatment group (Groups 1 and 2) and the the higher increase in serum iron concentration, while in Group
serum iron concentration was measured before (time zero) and 2 (ferrous sulphate) and Group 3 (control), serum iron levels
30 min, 1, 2, 4, 6, 8 and 12 h after the bolus administration. are similar.

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N72

N72 Nutrafoods (2013) 12:N71-N78

These in vivo results represent only the first step of the increased conate), had a similar Hb increase (0.6 g/dl), but only the Sideral
bioavailability of UltraFer®. RM® iron group had a statistically significant increment
(p<0.0009).
Clinical studies Finally, we have recently performed a study on preterm babies
To demonstrate tolerability and effectiveness, eight different and preliminary data show that Sideral RM® (0.7 mg/kg BW)
human clinical trials have been performed with a food supple- increased Hb to an extent similar to that obtained after a three
ment, a finished product (Sideral RM®) containing UltraFer®. times higher daily dose of ferrous sulphate (2 mg/kg BW) after
3 months corrected ages.
Tolerability We can conclude that Sideral RM®, thanks to its phospholipid
Sideral RM® was administered to 17 iron-deficient adults with membrane vehicle, increases iron absorption and bioavailability
chronic kidney disease not tolerating oral ferrous sulphate. and, at the same time, prevents contact between iron and the
Sideral RM® was supplied in a daily dose of 30 mg for 3 months. gastrointestinal tract, reducing reaction with oral and gastroin-
A tolerability questionnaire was administered at the final visit testinal mucosae, thus improving tolerability.
and 100% of patients reported no side effects and better com-
pliance than ferrous sulphate. Safety
Similar results were obtained in a total of 80 healthy pregnant The in vivo study on rats and clinical human studies indicate
women study (14 mg or 28 mg Sideral RM® from the 28th week that UltraFer® is not toxic after oral administration.
of pregnancy). During pregnancy we have also seen prevention
of IDA. In fact, our data show the beneficial effect of Sideral Application and dosage
RM® on birth weight and prevention of maternal anaemia. UltraFer® is a ferric pyrophosphate food supplement (no novel
Moreover, 14 mg of formulation shows the same effect as 30 foods) in accordance with EU regulations. It is gluten free, GMO
mg of ferrous iron sulphate on haematological parameters, thus free and BSE free.
allowing a reduction in doses and side effects. UltraFer® is a white, odourless, tasteless, dispersible powder that
can be applied for food supplements like hard capsules, softgels,
Efficacy mouth-dispersible powders, water-dispersible syrups (alone or
A total of 72 adult cancer patients with chemotherapy-related in combination with other ingredients, vitamins and minerals)
anaemia were supplemented with Sideral RM® 30 mg daily in and functional foods, i.e., milk, yoghurt, beverages, bars).
combination with Epoetin Alfa for 8 weeks. From baseline, an
average increase of Hb levels of 2.2 g/dl was observed, together
with an improvement of quality of life measured through a Alesco in a nutshell
specific questionnaire (FACT-An).
These Hb increments are very similar to those observed after Alesco is an Italian company that boasts exclusivity for the distri-
intravenous (i.v.) iron therapy. For this reason we decided to bution of functional ingredients chosen from the world’s most
important producers. The products distributed by Alesco are all
perform two clinical trials comparing Sideral RM® to i.v. iron
innovative, patented, branded and effective. Their efficacy is con-
administration.
firmed by published clinical studies. After years of scientific re-
In the first study, 24 adults affected by myelodysplastic syndrome
search, Alesco has developed its proprietary line of functional
refractory anaemia taking iron (group 1: 30 mg oral Sideral RM® ingredients: UltraMins and UltraMir, entirely made in Italy, for
daily; group 2: i.v. sodium ferric gluconate) in combination with the global market.
Epoetin Alfa, Sideral RM® increased Hb by 1 g/dl after just 5
weeks vs. 4 weeks with i.v. iron. At the end of the observation For information
period, both groups had an equivalent increase of Hb (3 g/dl). Germano Tarantino
In the second study, 21 adults with chronic kidney disease, after tel +39 050 7846511
email dir.tecnica@alescosrl.com
8 weeks of supplementation (Group 1: 14 subjects, 30 mg oral
web www.alescosrl.com
Sideral RM® daily; Group 2: 7 subjects, i.v. sodium ferric glu-

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N73

Nutrafoods (2013) 12:N71-N78


N73

Curcumin C3 Reduct®
The next generation of curcuminoids
by Sabinsa
© Springer Healthcare – CEC Editore 2013

Sabinsa’s scientific team has developed Curcumin C3 Reduct®,


Physical and chemical properties
a standardised extract from Curcuma longa (turmeric) plant rhi-
Appearance Creamy white to pale yellow
zomes with new technical features, such as white colour and crystalline powder
improved bioavailability. Solubility Soluble in acetone, insoluble
Curcumin, obtained from one of the most revered plants in the in water
traditional Indian ayurvedic system, has been in focus for its Moisture (%w/w) 1max
Residue on ignition (%w/w) 1max
health benefits including its hepatoprotective, antioxidant, anti-
Sieve test 80 mesh (%w/w) 70 min
inflammatory and antihyperlipidaemic activity. However, its
limited stability at phisiological pH, limited bioavailability and Microbiological properties
the vivid colour of curcumin are of great concern for manufac- Total viable aerobic count (cfu/g) <5000
Mould/yeast (cfu/g) <100
turers and consumers.
Escherichia coli neg/10 g
Curcumin C3 Reduct is the result of recent research into metabo-
Salmonella neg/10 g
lites of curcumin that has revealed the role of tetrahydrocurcum-
Staphylococcus aureus neg/10 g
inoids (THCs) as not only the major metabolites but also as an Pseudomonas aeruginosa neg/10 g
active compound superior to the curcuminoids themselves. In Bile-tolerant gram-negative bacteria neg/10 g
addition, tetrahydrocurcumin may be more easily absorbed from
Chemical composition (typical values)
the gastrointestinal tract than curcumin itself [1]. Curcumin C3
Total THCs (HPLC) (% w/w) 95 min
Reduct is marketed in the United States as a dietary supplement Excipients None
ingredient, while in the European Union it is considered a novel
Shelf life 2 years
food. In Japan, Curcumin C3 Reduct is sold as a health food/di-
Storage Room temperature
etary supplement ingredient. In Canada, the Master file is cur-
rently being submitted to the Natural Health Products Directorate. Table 1 Finished product specification for Curcumin C3 Reduct

Composition
Curcumin C3 Reduct® is a biostandardised extract and is kosher and THC were evaluated using a 1,1-diphenyl-2-picrylhydrazyl
certified. As a standardised extract with actives responsible for (DPPH) radical scavenging method. The results, shown in Fig.
its bioactivity, its biological activity is ensured and consistent 1, indicate that all test compounds resulted in significant neu-
in every batch. Curcumin C3 Reduct is obtained by hydrogenat- tralisation of free radicals in a dose-dependent manner, with
ing the curcuminoids from the rhizomes of the C. longa THC being the most effective, followed by curcumin and BDMC.
(turmeric) plant. These rhizomes are harvested and sun-dried Curcumin C3 Reduct inhibited the brain inflammatory marker
before extraction to obtain the natural curcumin. The curcumin interleukin-1β better than curcumin in the acute and chronic
thus obtained is processed under proprietary conditions to pro- inflammation model [3].
vide an extract containing 95% THCs. THC was found to be more effective than curcumin in lowering
THCs present in Curcumin C3 Reduct® do not stain, unlike the brain lipid peroxidation products, namely F2 isoprostanes, with
curcuminoids, which are yellow; and they are photostable, un- an EC50 value of 0.501 µM compared to curcumin’s 1.067 µM [3].
like curcuminoids, which decompose in sunlight. Studies have shown that THCs have better activity than cur-
Moreover, THCs are more stable at physiological pH (7.2). The cumin in lowering serum lipids (Fig. 2): it reduced the serum
technical features of Curcumin C3 Reduct are shown in Table 1. low-density lipoprotein and very-low-density lipoprotein, and
increased levels of high-density lipoprotein in diabetic rats [4].
Preclinical studies THC showed an antihyperlipidaemic effect in a streptozotocin-
THC, the active compound of Curcumin C3 Reduct, exerts a nicotinamide-induced oxidative stress animal model. The mem-
greater antioxidant activity than curcumin in both in vitro and brane-bound antioxidant enzymes were increased significantly
in vivo systems [1, 2]. Okada et al. have claimed that THC has on THC treatment. Oral administration of THC also prevented
more potent antioxidant activity than curcumin [1]. changes in the levels of fatty acids, glucose and insulin in the
In a series of studies conducted by Sabinsa, the free radical scav- blood of a diabetic model. Studies showed that THC significantly
enging ability of curcumin, bisdemethoxycurcumin (BDMC) decreased lipid peroxidation in different tissues and compared

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N74

N74 Nutrafoods (2013) 12:N71-N78

BDMC Curcumin Tetrahydrocurcumin


80

70

60

50
% inhibition

40

30

20

10

0
10 20 30 40 50
Concentration (µg/mL)

Figure 1 Effect of curcumin, BDMC and THC on inhibition of DPPH formation

on the oral intake. (Please contact Sabinsa for study details.)


200
180 Acute oral toxicity of THCs in rats is >5000 mg/kg body weight.
160
Serum lipids (mg/dL)

140 Applications and dosage


120 As a colour-free extract with better solubility and pH stability
100 than curcuminoids, Curcumin C3 Reduct provides more for-
80
mulation options to manufacturers.
60
Curcumin C3 Reduct can be formulated in tablets, capsules and
40
20 powdered dosage forms, as well as in beverages. It can be for-
0 mulated in soft capsules and gummies. Due to its non-staining
Control Diabetic Diabetics+THCs Diabetics+ nature, it can also be used in oral hygiene products such as
rats control (80 mg/kg) Curcumin toothpaste, dental creams and washes.
(80 mg/kg)
Curcumin C3 Reduct® can be used for the management of ox-
idative stress and inflammation.
Figure 2 Effect of curcumin and THC on serum cholesterol
level in diabetic rats The suggested use levels are 200–400 mg extract in two divided
doses for nutritional purposes.

with similar treatment doses of curcumin, has a much greater References


antidiabetic effect [5]. 1. Okada K, Wabgpoenqtrakul C, Tanaka T, Toyokuni S, Uchida
The anti-angiogenic effect of THC is higher than that of cur- K, Osawa T (2001) Curcumin and especially Tetrahydrocur-
cumin [6]. THC was found to express its anti-angiogenic poten- cumin ameliorate oxidative stress induced renal injury in
tial without any cytotoxic activities to HepG2 cells, even at the mice. J Nutr 21:2090–2095
highest doses. It is suggested that the anti-angiogenic properties 2. Pari L, Murugan P (2004) Protective role of tetrahydrocur-
of curcumin and THC represent a common potential mechanism cumin against erythromycin estolate induced hepatotoxic-
for their anti-cancer actions [6]. ity. Pharmacol Res 49:481–486
3. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath
Safety DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF,
Curcumin C3 Reduct has a very good safety profile in humans. Teter B, Cole GM, Frautschy SA (2008) Curcumin structure-
In a clinical study performed to establish the safety of dietary function, bioavailability and efficacy in models of neuroin-
supplements in healthy subjects for 28 days using 300 mg once flammation and Alzheimer’s disease. J Pharamcol Exp Ther
daily, C3 Reduct showed 100% compliance with no side effects 326(1):196–208

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N75

Nutrafoods (2013) 12:N71-N78


N75

4. Pari L, Murugan P (2007) Antihyperlipidemic effect of cur- man and Mother Nature. Biochem Pharmacol 76:1590–
cumin and tetrahydrocurcumin in experimental Type 2 di- 1611
abetic rats. Renal Failure 29:881–889 6. Yoysungnoen P, Wirachwong P, Changtam C, Suksamram
5. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, A, Patumraj S (2008) Anti-cancer and anti-angiogenic effects
Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarshini of curcumin and tetrahydrocurcumin on implanted hepa-
IK, Rajasekharana KN, Aggarwal BB (2008) Biological activ- tocellular carcinoma in nude mice. World J Gastroenterol
ities of curcumin and its analogues (Congeners) made by 14(13):2003–2009

Sabinsa in a nutshell

Sabinsa Corporation, founded in 1988, is a manufacturer and supplier of herbal For information
extracts, cosmeceuticals, minerals and specialty fine chemicals. Sabinsa’s mission is to Sabinsa Europe GmbH
provide alternative and complementary natural products for human nutrition and Germany
well-being. Over the past twenty years, Sabinsa has brought to market more than 100 tel +49 6103 27011 11
email info.europe@sabinsa.com
standardised botanical extracts and privately funded several clinical studies in con-
web www.sabinsa.com
junction with prestigious institutions in support of these products. Its present operations
have grown to employ 1000 people worldwide in ten manufacturing, R&D and distri-
bution facilities. Additionally, botanical cultivation efforts undertaken by the organisation
now total nearly 40,000 acres to ensure sustainable supplies of its key products. All
products intended for human consumption are certified kosher and halal.

Fibregum™
A multi-functional, natural, soluble dietary fibre
by Nexira

© Springer Healthcare – CEC Editore 2013

Nexira began very early to focus its research on the nutritional charide, purified through only physical methods that involve
benefits of acacia gum as a native source of soluble dietary fibre no chemical processing or enzymatic modification. Fibregum™
and to develop the unique and innovative product line branded is odourless, colourless and flavourless, available as a free-flowing
as Fibregum™. powder. Fibregum™ is extremely resistant to heat treatments
The Fibregum™ portfolio is an all-natural and GMO-free source and acidic conditions, it is stable in broad temperature and pH
of 90% soluble dietary fibre (AOAC 985.29 method) sourced ranges, and is not degraded or hydrolysed.
from carefully selected Acacia trees, which grow mainly in semi- The soluble fibre in Fibregum™ has a negligible glycaemic index
desert regions of Africa. Acacia gum is the sap exuded from the (GI), because it is not digested in the small intestine, but further
stems and branches of Acacia trees and has been safely and ef- down the intestinal tract. Fibregum™ has a caloric value near 2
fectively used in the global food industry for decades. The joint kcal/g, which is an advantage in formulating reduced calorie
Food and Agriculture Organization (FAO)/WHO expert com- foods. It is non-cariogenic and non-erosive for teeth, as certified
mittee on food additives recognises acacia gum as a food additive by Toothfriendly International.
(INS 414) that can be used with no specified acceptable daily Technical specifications are reported in Table 1.
intake (ADI). In the United States, acacia gum enjoys a generally
recognised as safe (GRAS) classification. In Europe, acacia gum Efficacy
is recognised as a food additive under the quantum satis princi-
ple. In 2001, French regulators officially recognised acacia gum Glycaemic index
as a dietary soluble fibre, which allows the fibre content of In a crossover study done in collaboration with INA Food In-
acacia gum to be utilised for nutritional labelling. dustry (Japan), 12 healthy male subjects received 100 g of sucrose
plus 0, 5 and 10 g of Fibregum™, dissolved in 300 ml of water.
Composition and technical features Blood samples were taken from each subject before examination
Fibregum™ is a non-digestible, high-molecular-weight polysac- and at 30-min intervals for 150 min after supplementation. Re-

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N76

N76 Nutrafoods (2013) 12:N71-N78

from white bread (100 g) as reference food, and seven days later
Organoleptic properties
the same reference product added to 15 g of Fibregum™, dis-
Appearance Free-flowing powder
Colour Colourless solved in 180 ml of water. Capillary blood samples were taken
Taste Flavourless after a 14-h overnight fasting period, and then 30, 60, 90, 120,
Odour Odourless 150 and 180 min after having consumed the product for gly-
caemia analysis. The results (Fig. 1) show that, compared to the
Physical and chemical properties
Total dietary fibre (% on dry weight) >90 reference, the area under the blood glucose curve was reduced
Moisture (%) <10 by 18.6% with Fibregum™ [1].
Ashes (%) <4 In a study conducted using internationally recognised GI
pH (25% aqueous solution) 4.0–5.0 methodology, a group of 12 healthy non-smoking people (mean
Viscosity (25% aqueous solution, mPa) 70–130 age=23.5, body mass index (BMI)=21.6 kg/m2) were recruited.
Mesh size powder (%) 15 Four crispbreads, the reference with 50 g glucose and three
Microbiological properties without glucose, but with 4.1, 7.7 and 9.2 g of Fibregum™
Total plate count (cfu/g) <2000 used as food, were served to the subjects in fixed portions con-
Escherichia coli Absent/5 g taining 50 g of digestible carbohydrates. A fasting blood sample
Salmonella Absent/25 g was collected, and then additionnal blood samples were ob-
Maximum storage 3 years tained 15, 30, 45, 60, 90 and 120 min after eating. A GI value
Storage condition In a cool, dry place of each test food for each of the 12 subjects was obtained. The
concentration of insulin in each plasma sample was also meas-
Table 1 Technical specifications of Fibregum™
ured and, in a similar way, an insulinemic index (II) value for
each test food was calculated (Fig. 2). The results for the three
crispbreads containing the varying amounts of Fibregum™ in-
sults showed that the glucose concentration was significantly dicated a dose–response relationship on the GI values, with
lowered in the Fibregum™ groups as compared to the control the highest dose of Fibregum™ producing the lowest GI values.
group. In particular, the glucose level peak at 30 min after sup- The same outcome was obtained with the II. All three crisp-
plementation decreased to 153.5±7.5 mg/dl for 5 g ingestion breads produced II values that were proportional to their GI
and to 146±9.8 mg/dl for 10 g ingestion, as compared to values. Therefore, crispbreads 2 and 3 containing Fibregum™
171±7.65 mg/dl for the control group [1]. would be more suitable than crispbread 1 for consumption by
The reduction of the GI due to Fibregum™ consumption was people with diabetes [1].
also proven in a study focused on volunteers suffering from Although, according to the European Food Safety Authority,
Type 2 diabetes, done in collaboration with the Institute of Nu- the relationship between the consumption of acacia gum and
trition RAMS (Moscow, Russia). reduction of post-prandial glycaemic responses is not sufficiently
Fourteen diabetic, overweight or obese women (mean age=58.3 substantiated [4], the discussion between partners is still open
years, mean weight=89.3kg) were involved in the study. During and under review, potentially leading to positive opinions in
the first period they consumed 50 g of available carbohydrate the future.

15 GI II
120
Glycaemia (mmol/L) evolution (n=7)

13 100
Index average value

80
11

60
9
40
7 50 g of white bread
50 g of white bread + 15 g Fibregum 20

5
T0 T+30 min T+60 min T+120 min T+180 min 0
Bread #1 Bread #2 Bread #3 Glucose

Figure 1 Effect of Fibregum™ ingestion on glycaemic response Figure 2 Mean glycaemic and insulinaemic values
in diabetic women for the three crispbreads and the reference food

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N77

Nutrafoods (2013) 12:N71-N78


N77

Sucrose 10 g/d Fibregum10 g/d

Lactobacilli

Bifidobacteria

Lactic bacteria

Bacteroides

Anaerobes

8 9 10 11

Figure 3 Concentrations of lactic adic bateria in the stool after 10 days of Fibregum™ intake (10 g/day) compared to control

Prebiotic effects for cereal bars, which eliminates the need to add lecithin. It
The bifidogenic properties of Fibregum™ were confirmed in a can be used for fortifying cereal bars at 6%–8% by weight.
single-blind controlled study performed on healthy volunteers As a prebiotic fibre, Fibregum™ can be used to develop innova-
consuming either Fibregum™ at a dose of 10 g/day and 15 tive functional foods thanks to its very high digestive tolerance
g/day for 10 days, or sucrose as a control at the same dose. This up to the dose of 50 g/day. Fibregum™ can be used for fibre en-
study showed that stool concentrations of bifidobacteria, lacto- richment of low GI products. Fibregum™ enrichment also allows
bacilli and total lactic acid bacteria groups were significantly a reduction in the level of polyols or sucrose, while maintaining
increased with Fibregum™ at doses of 10 g/day and 15 g/day as the same binding properties of syrup. It is also very compatible
compared to controls (Fig. 3). with other common confectionery ingredients such as gelatine,
The fermentation pattern of Fibregum™ results in the production starch and other hydrocolloids. For example, traditional gum
of beneficial short-chain fatty acids (SCFAs) propionate and bu- pastilles containing 45%–50% acacia gum can be positioned as
tyrate. Moreover, it is progressively fermented by probiotics in a nutritional confectionery if formulated with Fibregum™, with-
the intestinal tract without discomfort; total gas production is out modification of the typical processing conditions. In chewy
much lower than with fructo-oligosaccharides (FOS) [5]. candies, it can be added at 1%–4% to typical formulations.

Tolerability References
Studies in human volunteers confirm that ingestion of Fi- 1. Castellani F (2005) Product focus. Fibregum™ (Acacia gum)
bregum™ is well tolerated even at high doses (50 g/day). Also, helps reduce the glycemic index of food products. Agro
the symptoms (flatulence, bloating, borborygmi, cramping) as- Food Industry Hi Tech 16:24–26
sociated with doses as high as 30 g/day of Fibregum™ were 2. EFSA Panel on Dietetic Products, Nutrition and Allergies
similar to those with the sucrose control. In addition, Fi- (NDA) (2010) Scientific opinion on the susbtantiation of
bregum™ was much better tolerated than FOS. health claims related to acacia gum (gum arabic) and reduc-
tion of post-prandial glycaemic responses and maintenance
Applications and dosages of normal blood glucose contentrations pursuant to Article
Thanks to its high and instant solubility, Fibregum™ can be 13(1) of Regulation (EC) 1924/2006. EFSA J 8(2):1475–1489
easily added into food systems with no impact on viscosity. Fi- 3. Cherbut C, Michel C, Raison V, Kravtchenko T, Meance S
bregum™ can be used in various products including beverages, (2003) Acacia gum is a bifidogenic dietary fibre with high
confectionery, baked products, dairy products, cereals and di- digestive tolerance in healthy humans. Microb Ecol Health
etary supplements. Fibregum™ is also an efficient emulsifier Dis 15(1):43–50

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N78

N78 Nutrafoods (2013) 12:N71-N78

Nexira in a nutshell

Created in 1895, the family-owned company Nexira is a world leader in natural in- For information
gredients and botanical extracts for food, nutrition and dietary supplements. Nexira Mathieu Dondain
has built its reputation as the world leader in acacia gum and now offers a wide Director of Marketing & Communication
range of natural ingredients with proven health benefits. The company indeed benefits tel +33 232 83 18 18
email v.agnolutto@nexira.com
from over 100 years of experience in sourcing raw materials from several African
web www.nexira.com
countries and provides ongoing support to developing new growing regions. Their
knowledge of different varieties of gum and the long-term relationships established
with local partners in Africa are strong assets which contribute to the final ingredient
quality, availability and traceability. In order to offer customers the highest quality
standards, Nexira establishes strict quality controls at each step of the production
process, from the harvesting of acacia gum to the delivery of the final ingredient.
Nexira's commitment to quality is supported by ISO 9001 certification since 2003
(ISO 9002 since 1995), and more recently the British Retail Consortium (BRC) certi-
fication for quality. The company has also developed a thorough HACCP program
and closely monitors regulatory requirements globally such as the new Food Safety
Modernization Act in the United States. Nexira is focused on continuous improvement
in quality management and constantly strives to exceed customer expectations..

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N79

Nutrafoods (2013) 12:N79-N82


DOI 10.1007/s13749-013-0047-1

News of Industry N79

Indena in Tours
Successful outcome from FDA inspection

© Springer Healthcare – CEC Editore 2013

Indena announces that its French production site in Tours “We are pleased with the successful outcome of the FDA in-
(France) successfully passed the U.S. Food and Drug Adminis- spection,” said François Mairel, Indena Tours Plant Director. “The
tration (FDA) inspection, with no FDA-483 issued, as per the audit covered the manufacturing of important products we are
Establishment Inspection Report (EIR) received from the Center selling to our U.S. customer base, including grapeseed, olive
for Food Safety and Applied Nutrition of the FDA. This confirms polyphenolic and ginkgo biloba extracts, and further confirms
that the company meets the new requirements mandated by our commitment to giving our customers the highest standards
the FDA Food Safety Modernization Act (FSMA). of quality.”
The inspection involved the entire organisation and focused Indena Tours previously obtained the following certifications:
on manufacturing operations, hazard analysis and critical con- GMP Certificate from the French Health Ministry – ANSM,
trol point (HACCP), sanification, cleaning, recall, complaint HACCP, ISO 14001, and kosher and halal certificates.
and training programmes and procedures.

Indena in a nutshell

Indena is the leading company dedicated to the identification, development and For information
production of active principles derived from plants, for use in the pharmaceutical, Cohn & Wolfe Milan
health food and personal care industries. Backed up by 90 years of botanical experi- Laura Faravelli
ence, the company has more than 120 primary patents and has published more laura.faravelli@cohnwolfe.com
Lorenzo Petracco
than 700 scientific studies and cooperates with the world’s most prestigious univer-
lorenzo.petracco@cohnwolfe.com
sities and private research institutions. Indena employs about 800 staff, investing
tel +39 02 202391
around 10% of its annual turnover in research, making this activity the key to its suc- Twitter: @IndenaSpA
cess. Headquartered in Milan, Indena has 5 production sites and 4 international www.indena.com
branches throughout the world and manages sales in more than 70 countries. The
company's experts communicate and interact constantly with the major international
regulatory authorities such as WHO, EMA and ESCOP, and cooperate on the update
of all the main pharmacopoeias.

DuPont
Opens probiotics facility in China

© Springer Healthcare – CEC Editore 2013

DuPont has launched production at its state-of-the-art probiotic In 2011, DuPont purchased a food processing plant north of
blending and packaging facility in China. The new site in Bei- Beijing and converted it into a new cutting-edge probiotic blend-
jing represents DuPont Nutrition & Health’s first step in pack- ing and packaging site to serve dietary supplement and food
aging probiotics into ready-to-market formats that allow and beverage customers globally and more specifically in China
DuPont to offer its customers improved speed to market, quality and the Asia Pacific region. The investment is part of a global
and flexibility. Investment and capacity have not been dis- multi-year capacity expansion programme for cultures and pro-
closed. biotics in the United States, Europe and now in China.

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N80

N80 Nutrafoods (2013) 12:N79-N82

“Probiotics is a fast-growing segment of our business and the


DuPont in a nutshell
industry is experiencing double-digit growth rates annually
around the world and in China,” said Fabienne Saadane-Oaks,
DuPont Nutrition & Health addresses the world’s challenges in
vice president of health and protection, DuPont Nutrition &
food by offering a wide range of sustainable, bio-based ingredi-
Health. “As we continue to support the world’s growing popu- ents and advanced molecular diagnostic solutions to provide
lation, this expansion allows us to custom blend and package safer, healthier and more nutritious food. Through close collab-
high-quality probiotic products for our customers in the fast- oration with customers, DuPont combines knowledge and ex-
growing dietary supplement and food and beverage industries perience with a passion for innovation to deliver unparalleled
close to our customers, where we want to be.” customer value to the marketplace.
The new facility will allow customers to source ready-to-market DuPont has been bringing world-class science and engineering
probiotic formulations consisting of Danisco® HOWARU® pre- to the global marketplace in the form of innovative products,
mium and FloraFIT® custom probiotic brands. And, by DuPont materials and services since 1802. The company believes that
by collaborating with customers, governments, non-governmen-
managing the process throughout, customers will be assured of
tal organisations and thought leaders we can help find solutions
the highest standard of food safety and quality.
to such global challenges as providing enough healthy food for
“This expansion is a further reinforcement of DuPont’s long-
people everywhere, decreasing dependence on fossil fuels, and
standing commitment to China, our customers and consumers. protecting life and the environment.
We are actively helping to address some major challenges facing
the world, including the need for nutritious and quality food, For information
resulting from population growth and urbanisation,” added Cathy Andriadis
Tony Su, president of DuPont Greater China. tel +1 302-695-2212
catherine.l.andriadis@dupont.com
The probiotic formulations offer unique improvements for di-
www.dupont.com.
gestive and immune health and other well-being benefits in
the dietary supplement, dairy and beverage markets. Probiotic
cultures will be sourced from the company’s North American pected to increase to $45 billion by 2018. More than 90% of the
and European sites. The new facility in China will be able to total is attributed to food, beverage and dietary supplements.
custom blend the ingredients to meet the requirements of local DuPont has eight sites in China that provide a range of food in-
customers. China is already a significant market for the YO- gredients, from emulsifiers, hydrocolloids (blended ingredients),
MIX® dairy cultures from the DuPont™ Danisco® range. enzymes and sweetener ingredients to food protection ingredi-
According to industry estimates, in 2012 the market for probi- ents, soy protein, lecithin and fibre, and molecular diagnostic
otics globally totalled more than $32 billion. That total is ex- solutions.

DSM's new publication


The Road to Good Nutrition

© Springer Healthcare – CEC Editore 2013

Part of DSM and Sight and Life’s Vitamins in Motion campaign, From stunting to food insecurity, from hidden hunger to obesity,
the new book entitled The Road to Good Nutrition: A Global Per- the book puts the topic of nutrition security on the agenda of
spective brings together experience and insights of globally recog- policymakers, academics, private sector organisations and civil
nised experts in the field to forge collective action on malnutri- society, as well as of organisations dedicated to the field of nu-
tion. This major publication on best practices in nutrition was trition. It will also be of value to the educated lay reader who is
presented at the 20th International Congress of Nutrition in generally well informed in matters of health, nutrition and sus-
Granada (Spain), 15–20 September 2013. It is part of DSM’s Vi- tainability.
tamins in Motion initiative, which highlights the critical role Published by the Swiss-based scientific publisher Karger, The
micronutrients play in health, wellness and disease prevention Road to Good Nutrition: A Global Perspective explains that malnu-
throughout the life cycle and advocates for increased access to trition is a phenomenon with many aspects, not all of them
these essential vitamins. immediately apparent. Approximately a third of the world’s

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N81

Nutrafoods (2013) 12:N79-N82


N81

children face lifelong economic and social disadvantage because Patrick Webb, Dean for Academic Affairs, Friedman School of
of poor nutrition during pregnancy and in the first two years of Nutrition Science and Policy, Tufts University, Boston, com-
life. A significant proportion of these children are disadvantaged ments: “This book represents a rallying cry. It is a call to action
because of unbalanced diets that lead to obesity and its associ- to address a massive unfinished global agenda. Undernutrition
ated health challenges. in all its forms is still responsible for almost half of the world’s
In his foreword to the book, David Nabarro, Special Representa- child mortality. Other malnourished children survive, but they
tive of the UN Secretary-General for Food Security and Nutrition cannot thrive. The Road to Good Nutrition pulls together the
and Coordinator of the Scaling Up Nutrition (SUN) Movement, latest evidence on underlying causes and priority solutions. It
writes: “The Road to Good Nutrition brings together the experience demands to be widely read, and its findings deserve to be taken
and insights of globally recognised experts in the field of nutri- very seriously.”
tion to create an in-depth introduction to the subject for the Webb’s judgement is echoed by Marie Ruel, who observes, “The
non-expert. My hope is that The Road to Good Nutrition will Road to Good Nutrition provides an in-depth and broad overview
help us all to accelerate our progress along the path to a world of the critical challenges we are facing in nutrition today. It
where everyone receives the food and the nutrition to which should help policymakers and development practitioners make
they have a self-evident right.” more informed choices about priorities and actions to accelerate
The Road to Good Nutrition was developed under the guidance progress in achieving nutrition for all in the near future.”
of an editorial board led by Manfred Eggersdorfer, Senior Vice The full text of The Road to Good Nutrition and its executive sum-
President of DSM Nutrition Science and Advocacy. It draws es- mary can be downloaded from www.vitaminsinmotion.com.
pecially on the insights of Klaus Kraemer, Director of DSM’s nu-
trition think tank Sight and Life, and Marie Ruel, Director of the
Poverty, Health and Nutrition Division, International Food Pol- DSM in a nutshell
icy Research Institute (IFPRI), Washington DC. Ruel contributed
to the landmark 2013 Lancet series on Maternal and Child Nu- Royal DSM is a global science-based company active in health,
nutrition and materials. By connecting its unique competences
trition. The editorial board also includes the following members:
in life sciences and materials sciences, DSM is driving economic
Marc Van Ameringen, Executive Director of the Global Alliance
prosperity, environmental progress and social advances to create
for Improved Nutrition (GAIN); Hans Konrad Biesalski, Head of
sustainable value for all stakeholders. DSM delivers innovative
Department, Biological Chemistry and Nutrition, University of solutions that nourish, protect and improve performance in
Hohenheim; Martin Bloem, Senior Nutritionist and Global Co- global markets such as food and dietary supplements, personal
ordinator of the United Nations World Food Programme (WFP) care, feed, pharmaceuticals, medical devices, automotive, paints,
and UNAIDS; Junshi Chen, Senior Research Professor, Institute electrical and electronics, life protection, alternative energy and
of Nutrition and Food Safety, Chinese Center for Disease Control bio-based materials. DSM’s 23,500 employees deliver annual
and Prevention, Beijing, China; Asma Lateef, Director, Bread net sales of around €9 billion. The company is listed on NYSE
for the World Institute, Washington, DC,; and Venkatesh Man- Euronext. More information can be found at www.dsm.com.
nar, President of the Micronutrient Initiative.
For information
The Road to Good Nutrition serves as a call to concerted action— DSM Nutritional Products
functioning as a guidebook for those wishing to find out more External Communications
about this topic and encouraging readers to take an active part in Charlotte Frederiksen
this global journey themselves. The book summarises the progress tel +41 61 815 83 54
charlotte.frederiksen@dsm.com
and commitments made to date, and outlines the road ahead to
www.dsm.com
ensure all people receive the basic human right to good nutrition.

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N82

N82 Nutrafoods (2013) 12:N79-N82

LycoRed
Appoints Marlene Comon as Regional Sales Manager in France

© Springer Healthcare – CEC Editore 2013

LycoRed has appointed Marlene Comon as Regional Sales Man- of food safety and health issues—consumers demand natural
ager for the French food and beverage market. Comon will en- and healthy alternatives to artificial food colourings.”
hance LycoRed’s focus on marketing natural food colourants Comon was previously Account Manager in France for Tate
and vitamin and mineral premixes to food and beverage com- &Lyle from 2004 through 2012. She holds a master’s degree
panies. from the Ecole Superieure d’agriculture d’Angers, France, as well
Analysis of new product launches using natural colours tracked as a marketing degree from Wyoming University, United States.
by Innova Market Insights in France revealed a steady increase “The world colourant market is estimated at US$20 billion and
in activity through 2011 and 2012. In 2012, natural colours market growth is estimated to reach 10%,” notes Philippe Millet,
were used in 10% of products launched and the top market cat- managing editor of Actif’s Magazine. “The main markets are Eu-
egories for such launches were gums, cakes, pastries and sweet rope (US$7 billion), the United States (US$5 billion) and Japan
goods, ice cream and yogurt. (US$2 billion). The functional foods market in France is esti-
“It’s exciting to have Comon with her impressive track record mated at €2–3 billion, with the main categories being dairy,
as part of LycoRed’s EMEA sales team,” says Ilan Ron, EVP Global oils and margarine, breakfast cereals and bakery products.”
Sales & Marketing. “Her extensive experience in the food and
beverage market in France is an important asset, not just to Ly- LycoRed in a nutshell
coRed but also for the food and beverage developers in this im-
portant market.” LycoRed is a science-based company with regional facilities in
Adds Ron, “Comon brings many years of experience in sales for the United States, Europe, Israel and Asia. It supplies natural
the French food industry and has a vast knowledge of imple- carotenoids and a wide range of other natural nutritional and
menting sales strategies and managing key accounts and will colouring ingredients to the dietary supplement, functional food
be reporting to Laurence Le Goff, Global Key Accounts manager and beverage and nutricosmetic industries, worldwide.
for both the French and the overseas markets.”
For information
Ron points out that the shift toward natural food colourants in Karina Bedrack
the food and beverage market continues to grow, as “consumers Sales & Marketing Manager
associate natural with quality.” He adds, “The rising preference info@lycored.com
www.lycored.com
for all natural colours is also fuelled by the increased awareness

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N83

Nutrafoods (2013) 12:N83


DOI 10.1007/s13749-013-0042-6

Marketing N83

New food and drink launches containing vitamin K2


Almost doubled over the past five years globally
Mintel*
© Springer Healthcare – CEC Editore 2013

The global functional food market has been steadily increasing cardiovascular and bone health, its role could extend beyond
in recent years and manufacturers have become more and more these features with its growing list of health benefits such as a
innovative with the ingredients they include to bring benefit role in sports nutrition and possibly in the prevention of can-
to the consumer. But it seems there may be a new ingredient cer,” Laura adds.
that manufacturers are realising has great potential. Indeed, And it seems the various health benefits of vitamin K could ap-
new research from Mintel reveals new product launches con- peal to a considerable number of consumers. Indeed, over a
taining vitamin K2 have almost doubled (+183%) globally over third (35%) of UK consumers buy functional food and drink
the past five years (2008–2012). products to maintain a healthy heart and almost a quarter (24%)
Comparatively, the better known form of vitamin K, vitamin to lower blood pressure or cholesterol.
K1, posted a healthy, but slower growth (+90%) over the same Overall, the use of cardiovascular and bone health claims is
review period. Furthermore, looking at all food, drink, vitamin growing globally, with food and drink products holding bone
and supplement launches globally containing either vitamin health claims almost tripling in the past five years (+330%) and
K1 or K2, vitamin K1 was used in an overwhelming 96% of cardiovascular claims posting a healthy 66% growth over the
products, with the remaining 4% containing vitamin K2. past five years (2009/2012). Furthermore, the number of new
Laura Jones, Global Food Science Analyst at Mintel, said: “Vita- products with bone health claims has grown by 44% since 2009.
min K1 has a relatively short half-life and is rapidly cleared Cardiovascular benefits also appear to rank high on consumers’
from the blood and is cleared by the liver within eight hours. list of health priorities. In the UK, for example, maintaining a
In comparison, vitamin K2 has a longer half-life of up to 72 healthy heart and lowering cholesterol are among the leading
hours, meaning it remains biologically active in the body for health targets for consumers: 23% and 21% of consumers, re-
longer. Vitamin K2 is also absorbed better by the body compared spectively, indicated that they had tried to manage these health
with vitamin K1. These factors, along with the additional health areas in the last 12 months.
benefits linked to vitamin K2, should encourage the use of vita- Similarly, in the USA, a third of functional food consumers re-
min K2 over K1 when trying to correct vitamin K deficiency.” port eating these products in order to address hearth health
The most active categories of food and drink launches contain- and cholesterol concerns. Furthermore, these health concerns
ing vitamin K2 in 2012 are vitamins and dietary supplements, will only be heightened as consumers age. In the USA, half of
which account for the majority (76%) of new product launches functional food consumers aged 55–64 years say they eat these
globally, followed by baby formula (6%), beverage mixes (6%), products for heart health and cholesterol-lowering reasons. With
flavoured milk (6%) and soy-based drinks (6%). the global population ageing, the demand for functional prod-
This year (January to August 2013), while vitamins and dietary ucts that can assist with cholesterol looks set to increase.
supplements are still the most popular launches with K2 (58%), “This demonstrates recent interest in products targeting a global
Mintel research has recorded a higher penetration of soy-based ageing population. Increasing incidence of cardiovascular and
drinks (25%), drinking yogurts and cultured milk (8% respec- osteoporosis issues will mean bone and cardiovascular claims
tively). will continue to be a key focus for functional foods and supple-
“Vitamins and supplements continue to be the largest category ments, with women in particular being the main target for bone
in which vitamin K2 is used. However, ongoing research and health products, due to their higher incidence of osteoporosis.
ingredient companies’ promotion of vitamin K2 as a health in- The main bone health ingredients will continue to be calcium
gredient will likely to assist its uptake in more food and bever- and vitamin D, but as consumers’ awareness of vitamin K2 in-
ages. And while vitamin K2 has been traditionally associated to creases, its prevalence in food and supplements making a bone
health claim will increase. Effective cardiovascular ingredients
will be sought after too and vitamin K2’s potential in cardio-
* Mintel, global and award-winning provider of market research vascular health should be highlighted,” Laura concludes.

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N84

Nutrafoods (2013) 12:N84


DOI 10.1007/s13749-013-0043-5

Congress Report N84

The 7th Probiotics, Prebiotics & New Foods


Investments and Research on Microbiome
Rome, 8–10 September 2013
© Springer Healthcare – CEC Editore 2013

The reason for this meeting was that numerous unsolved prob- various biotransformations and indirectly by the expression and
lems regarding the microbiome remain. There is potential for activity of components of the host xenobiotic metabolism [2].
research in the following areas: host immune system and mi- During the opening ceremony of the meeting, Barbara Burlingame,
crobiome interactions, the microbiome and disease associations, Deputy Director of the Nutrition Division of the Food and Agricul-
functional interactions between host and microbiome, diet and ture Organization (FAO) reminded us that the nutrition division of
the microbiome, translational research and the microbiome, the FAO has occasionally focused its attention on prebiotics and
and faecal microbiome transplants. probiotics and in the FAO’s soon-to-be launched book, Milk and
About a year ago, one of the world’s leading financial journals, Dairy Products in Human Nutrition, pre- and probiotics receive promi-
The Economist, splashed the microbiome over its front page. Eco- nence in at least two chapters. In food composition work, dozens of
nomic analysis is at the centre of any system devoted to making prebiotic compounds have been assigned in food labels, and food
life easier, but raising grants remains one of the major problems composition data generators and compilers have been encouraged
of research. In recent years, huge investments have been made to add them to food composition tables and databases; moreover,
in this field. within expert consultation on food energy, recommendations were
In 2008, the National Institutes of Health (NIH) started up the made to assign energy values to a number of these components.
five-year Human Microbiome Project (HMP), which led to nu- The most interesting scientific contributions were presented by
merous important publications. Moreover, since 2002, the num- Francisco Guarner (Digestive System Research Unit Barcelona)
ber of journal articles on this topic published per year has in- and Joël Doré (INRA UMR 1319 Micalis & USR 1367 Metagenop-
creased tenfold. The publications in this field from 2002 to olis, Jouy en Josas, France). Francisco Guarner, showed the profile
2012 show a significant shift toward content generated by im- of the human microbiome obtained from the data of the Human
munologists (×14) and gastroenterologists (×16) (ISI Thomson Microbiome Project. The gene set is almost complete, with about
Web of Science, 2013). 106 Bacteria, 105 Archaea, 104 Fungi, 103 Protists, 104 Viruses/Phages
Now HMP2 has been granted $5 million per year from 2013 to and 106 unknown. The richness of the human gut microbiome
2015 in order to generate genomic and functional microbiome correlates with metabolic markers, with a significant difference
data. The International Human Microbiome Consortium (IHMC), between obese and non-obese subjects.
which includes research institutes from all over the world (but Joël Doré presented perspectives from gut microbiota studies
not from Italy) is involved in making large sums of money avail- for pharmaceutical or food applications, underlining the context
able to fund research on the human microbiome: $167 millions from today’s microbiomic view of the human intestinal micro-
in 2008 (Natite) and $290 millions in 2013. Moreover, some biota, with the recognition of microbiota’s role in triggering
start-ups are focusing on possible treatments based on the mi- and/or promoting maintenance of becoming chronic with a
crobiome, and major investments are being ploughed in: $4 mil- few recurrent features. Low species richness of intestinal micro-
lions for faecal transplants, $6 million to discover new treatments, biota is a recurrent feature of dysbiosis associated with intestinal
$8 millions to identify biomarkers for inflammatory bowel disease physiopathology. From these data it is possible to derive gut
(IBD) and non-alcoholic fatty liver disease (NAFLD) (Nature microbiota studies for pharmaceutical or food applications with
Biotechnology, 2013). a particular interest in microbiomic profiling for stratification-
Prebiotics and new foods are the other important topics of the based clinical and nutritional management. Finally, it is impor-
congress. Indeed the relationships between food and the micro- tant to remember that the next generation of drugs and dietary
biome are of relevance regarding carbohydrate degradation, sugar supplements will be functionalised by the microbiome. Novel
fermentation, gas production, protein degradation and amino drugs and new kinds of diets and functional foods will be derived
acid fermentation. There is also an important and complex inter- from metagenomic resources and microbiota modulation.
play between diet, gut microbiota and gastrointestinal transit [1].
Finally, the gut microbiota interact directly with drugs by catalysing References
1. Kashyap PC, Marcobal A, Ursell LK, Larauche M, Duboc H,
Earle KA et al (2013) Complex interactions among diet, gas-
Lucio Capurso (✉) trointestinal transit, and gut microbiota in humanized mice.
Rome, Italy Gastroenterology 144(5):967–977
lcapurso@libero.it 2. (2012) Science 336:1253–1255

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N85

Nutrafoods (2013) 12:N85-N87


DOI 10.1007/s13749-013-0044-4

Exhibition Report N85

Vitafoods Asia 2013


The nutraceutical industry gathers for insights into the business and marketing
Hong Kong, 3–4 September 2013
© Springer Healthcare – CEC Editore 2013

Building on the success of the last two editions, Vitafoods Asia The Vitafoods Asia Seminar Programme plays a significant role
2013 welcomed over 170 exhibitors showcasing a wide range in providing information about the business landscape in Asia,
of health food ingredients, raw materials and services to over which is essential for anyone wanting to do business across the
2200 visitors, buyers and distributors from across Asia. region. A workshop by European Advisory Services (EAS) Strate-
This event, focusing solely on nutraceuticals, functional food gic Advice on the forthcoming harmonisation process for health
and drink, and dietary supplements, serves an ever-growing in- supplements in the Association of Southeast Asian Nations
dustry in Asia Pacific, which, according to Euromonitor, saw sales (ASEAN) opened the Seminar Programme. The key message was
of health and wellness products worth US$ 217.4 billion in 2012, that companies need to understand the regulations and must
the largest across all regions. As consumer education about ben- start preparing for the forthcoming changes.
eficial health ingredients increases, interest has turned to forti- As Wai Mun Poon, Manager, Regional Regulatory Affairs, EAS Strate-
fied/functional products and milk formula and juice in particular. gic Advice Asia explains, “A number of developments in the area
The growing market in Asia is reflected in the increased daily at- of health supplement standards and regulation harmonisation
tendance figures at Vitafoods Asia (20% on the previous event). are underway in ASEAN and will be implemented by the ten
The international exhibitors included Aroma NZ, Biosearch Life, ASEAN member states within the next 5 years. While the har-
Coland Holdings, Croda, Chr. Hansen A/S, Golden Biotechnol- monisation will give opportunities for placing products with one
ogy Corp., Hedelab, Lycored, Naturex, Huisong Pharmaceuticals, common standard in multiple markets and making health claims,
Kaneka Corp, Lallemand Health Solutions, Novadiet, Planet companies should be aware that regulatory requirements are ex-
Ayurveda and TCI Co Ltd. A number of exhibitors participated pected to be tougher. Companies should understand the new re-
in Vitafoods Asia for the first time, and their feedback about quirements and plan their business strategies accordingly”
the quality of visitors was extremely positive. “This was the How to do business in China; understanding the regulatory en-
first Vitafoods Asia for Principle Healthcare and we were de- vironment in Hong Kong; and opportunities in winning health
lighted with the quality of distributors that we met from over trends were some of the other business-led presentations.
14 countries across Asia. We had a clear objective to meet with Keynotes by Euromonitor, Datamonitor and the Hong Kong
distributors from key strategic markets in Asia with a particular Food Science and Technology Association together with product
focus on Japan and Indonesia” said Darren Lister, International innovation presentations by Chr. Hansen, Winclove, Naturex
Sales Director of UK-based Principle Healthcare International. and DSM-HNH China collectively attracted almost 700 delegates.
Other exhibitors taking part for the first time included Private Vitafoods Asia is establishing itself as the forum for the industry.
Label Nutraceuticals, and spokesperson Mark Clark affirmed, “In Chris Lee, Vitafoods Portfolio Director, explains, “We launched
our first year exhibiting at Vitafoods Asia we found the visitors of Vitafoods Asia in response to requests from Western manufac-
high quality, making our travel from the USA well worth the trip”. turers, keen to launch and build their presence in Asia, and the
Many exhibitors are keen to secure deals with food manufac- region’s booming nutraceutical industry has created an even
turers and distributors across Asia and Vitafoods Asia was suc- greater need for a world-class platform. Our aim is to bring the
cessful in delivering visitors from all the major Asian countries. industry together, to provide a forum not just for business but
Over 30 countries were represented, with most attending from also for the exchange of knowledge and ideas.”
China, Hong Kong, Japan, India, South Korea and Malaysia. “Feedback from first-time and returning exhibitors has been
Portfolio Director Chris Lee stated, “Asia’s nutraceutical industry very positive; we struck the right note with the seminar pro-
continues to grow judging by the increased daily visitor atten- gramme, which had phenomenal turnout. Building on this
dance and the increased number of international exhibitors. year’s success, we are already planning for an expanded show
The opportunities for business across Asia are there for the in 2014,” adds Lee.
taking and our key objective is to provide the forum for ex-
hibitors and visitors alike to generate new business, meet the
key decision makers and get a better understanding of the key For information
issues for successful market penetration.” Catherine Mallaband – Vitafoods Asia press office
tel +44 (0) 20 7240 2444
Another indicator of growth and opportunity across Asia were catherine@stormcom.co.uk
the well attended sessions in the Seminar Theatre (attended by www.vitafoodsasia.com
over 30% of visitors).

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N86

N86 Nutrafoods (2013) 12:N85-N87

Nuce International and Food-ing International 2013


Two fairs make a successful event
Milan, Italy, 24–26 September 2013
© Springer Healthcare – CEC Editore 2013

Nuce International, the international fair for the nutraceutical, “We are really pleased with the agreement with BolognaFiere,
cosmeceutical, functional foods and drinks and health ingredi- which will enable the two events to develop and grow, thus
ents industry, and Food-ing International, the fair and confer- benefitting the entire sector,” says Marco Pinetti, president of
ence dedicated to ingredients for all sectors of the food and Artenergy Publishing. “I would, above all, like to stress how im-
beverage industry, closed their doors on Thursday 26 September portant the choice of Bologna is, being the capital city of the
with excellent results. Italian Food Valley.”
Together with Chem-Med, the Mediterranean Chemical Event, “This agreement shows how, in the Italian fair system, we need
which took place concurrently, the fairs took up an area of 15,000 to overcome local logics and create par excellence platforms,
square meters and were visited by more than 8000 operators. above all with regards to the more advanced and innovative
Next year the events will take place from 8 to 10 September at the sectors of our industry,” explains Duccio Campagnoli, president
Bologna fair centre, in the capital city of the Italian “Food Valley”. of BolognaFiere.
This important news will give an even stronger boost to the
two shows, which will be able to develop more and more into
specialist b2b reference events for their sectors during a strategic For information
project that includes synergic events. Davide Grassi – Press Office
The next edition of Nuce and Food-ing International will also tel +39 02 6630 6866
press@zeroemission.eu
be able to count on the scientific contribution of Artenergy
www.nuce.eu
Publishing, which created and launched the two events, which www.food-ing.eu
have become reference points for their sectors.

NutrEvent 2013
Where food, drug and ingredient actors converge
Lille, France, 19–20 June 2013
© Springer Healthcare – CEC Editore 2013

After receiving an invitation, I was delighted to participate in a discuss the main developments and new recruiting needs within
press trip to NutrEvent 2013 on behalf of the NutraFoods staff the sector.
from 19 to 20 June this year. Every two years NutrEvent brings According to Etienne Vernacke, General Commissioner of Nutr-
together all the major players involved in innovation processes
in nutrition and health. The objective is to foster and promote
Institut Pasteur de Lille
R&D collaborations in nutrition and health between the public
and private sectors. Institut Pasteur de Lille is a private foundation dedicated to sci-
The event offers a business convention, for one-to-one meetings, entific research. Founded 120 years ago, it integrated nutrition
at the core of the event; a program of specialised conferences, into its area of expertise in the 1980s. The Nutrition Department
entitled “Find out how to fill in the gap between research and assists numerous companies in the food industry with its R&D.
market”, composed of three parallel tracks introducing every Among its fields of expertise are the following: gut flora and
aspect of the innovation process; an international exhibition, immunology; eye health; weight management, glycaemic and
with 50 exhibitors; and a recruitment convention, a unique op- insulinaemic response, nutrition and psychological stress; and
lipid metabolism, obesity and cardiovascular disease.
portunity for training companies, industrialists and students to

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N87

Nutrafoods (2013) 12:N85-N87


N87

Event 2013 and General Manager of Eurosanté, the sector of


Tate & Lyle
food, nutrition and health is experiencing one of its most dy-
namic periods, dealing with consumers’ new requirements in
In September 2008, Tate & Lyle opened its Wellness & Nutrition
terms of sustainability and functional foods, new marketing
Centre in Lille. The centre includes laboratories and pilot plant
strategies, regulatory issues linked to the debates on health facilities for customers. It focuses on developing new ingredients
claims and emerging links between industry and academia. in the field of wellness and nutrition catering for beverages,
“The field is evolving and this requires adaptation in order to dairy, bakery and convenience food. The portfolio includes
transform these issues from threats into real opportunities.” sweeteners (from natural nutritive sources), texturants and well-
In the Lille region, there has been a huge amount of investment ness ingredients (soluble fibres, salt reduction).
in the fields of nutrition and health, and innovation is all
around. Thanks to its strategic position in Europe, in the centre
of the London–Paris–Brussels triangle, the Lille region is an Roquette
ideal location with direct access to Europe’s largest markets and
with a leading economic role in France and in Europe. Roquette is a French family group with an international dimen-
There is an agency, Eurosanté, devoted to helping French and sion. It processes plant-based raw materials: maize, wheat, po-
foreign companies active in the biology and health sectors to tatoes, peas and microalgae. One of the top five global leaders
establish themselves in Lille and Nord-Pas de Calais. in the starch manufacturing industry, it offers its customers a
A huge area is dedicated to hosting companies that would like wide range of products and solutions in the fields of human nu-
trition (49%), pharmacy–cosmetology (12%), paper/board
to join this huge cluster, called Eurosanté Bio-business Park, a
(12%), chemistry–bioindustry (10%) and animal nutrition (17%).
unique environment containing all the activities of the biology,
The company’s headquarters and research centre are in Lille.
nutrition and health sectors. The most renowned institutions
Three percent of turnover is devoted to R&D, where more than
based in the park include Centre National de la Recherche Sci- 300 people work. Their portfolio includes more than 5000 patents.
entifique (CNRS), France’s national centre for scientific research; Roquette provides five types of products: sugars and soluble fibres,
Institut National de Recherche Agronomique (INRA), the na- polyols, starches, proteins and derivatives, and fibres and oils.
tional institute for agronomic research; Institut Français de
Recherche pour l’Exploitation de la Mer (IFREMER), conducting
research into marine resources; and Institut Pasteur de Lille, a Copalis
foundation for research and public health.
Thanks to a programme of fiscal advantages, several interna- Copalis is a company specialising in the processing and market-
tional companies have moved into the region or located their ing of fish co-products. Copalis has developed a wide range of
headquarters there. Major international groups include Bayer marine ingredients for the functional food, nutraceuticals, health
Healthcare, GlaxoSmithKline Vaccines, Tate & Lyle and food, animal nutrition and cosmetics markets. The company is
Roquette. very experienced in enzymatic extraction and has a deep knowl-
edge of raw materials. Their products include hydrolysed collagen
Near Calais, in Boulogne sur Mer, there are several companies
protein, fish collagen, marine collagen, glycosaminoglycans, aro-
that exploit seafood in various ways. Boulogne sur Mer is the
matic extracts and salmon oil (food industry).
country’s most important harbour, with a huge turnover in
seafood, and has a long and outstanding tradition in the fishing
and seafood industry. Corrue-Deseille is a very impressive tradi- France, and leading businesses in the industry have chosen Lille
tional salting and smoking company. Its products include her- as their springboard for European growth. Easy access to leading
ring, salmon and haddock. consumer markets, abundant resources and a highly trained
Moreover the Lille region is the fourth-ranked food cluster in labour pool are the keys to our success.

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N88

Nutrafoods (2013) 12:N88


DOI 10.1007/s13749-013-0045-3

Exhibition Preview N88

Fi Europe
The food ingredients event of 2013
Frankfurt, Germany, 19–21 November 2013
© Springer Healthcare – CEC Editore 2013

With the global food ingredients market forecasted to grow in This year will see the return of the New Product Zone, which dis-
2013 by 2.7%, this industry is set to flourish and meet the re- plays the latest products and innovations and gives an inside
quirements of the ever-changing consumer trends. Given this scope of what is predicted in the future. The Innovation Tours are
development, as well as the population growth and the increas- also here, following the success of previous years. They will be
ing affluence of the developing world, the food ingredients in- following various topic trends and focus on the most innovative
dustry has become an intensely dynamic landscape. With the exhibitors around the show. The Industry Insight Theatre provides
relentlessness of the euro crisis coming to an end, finding the workshops and educational seminars on key industry topics, con-
best business partners, in this industry, has become more im- ducted by various associations, research companies and scholars.
portant than ever. The Seminar Sessions will allow exhibitors to present the latest
To help food producers find the most innovative ingredient innovations, cutting edge technology and product opportuni-
providers, UBM Live have organised the 2013 edition of Fi Eu- ties. The renowned Food ingredients Excellence Awards are pre-
rope & Ni, taking place on the 19–21 November 2013 in Frank- sented each edition, recognising the leading ingredient manu-
furt, Germany. Fi Europe has been the industry staple for over facturers and their latest innovations. The event is co-located
25 years and is the leading platform to source innovative ingre- with the Food ingredients Europe Conference, which covers issues
dients, grow market share and nurture business networks. The currently faced by the food ingredients industry and will provide
online visitor registration is now open for this unmissable event. crucial insights into leading scientific innovations and winning
Jana Farkasova, Business Development Manager, Nestlé, notes, marketing strategies and explore the hottest ingredient trends
“Fi Europe is a very useful tool to exchange information, make driving new product development and consumer spending in
contacts, enhance relationships and gain information about the F&B industry.
the latest trends and innovations.” Fi Europe is proven as the
most successful platform for companies to showcase themselves
in this vibrant and ever-growing market. Over 26,000 people For information
will be attending the show over the 3 days to unearth new busi- Nathalie Miller
ness partners, new suppliers and the latest innovations in the UBM Live
tel +31(0)20 409 9576
marketplace. Attendees at Fi Europe are looking for solutions to
nathalie.miller@ubm.com
further develop products in their pipeline, reformulate their ex- www.fi-europe.eu/PRregister
isting products and pursue cost-controlling solutions.

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N89

Nutrafoods (2013) 12:N89


DOI 10.1007/s13749-013-0046-2

Coming Events N89

Conferences 2013

November 5–6 November 21–22


Probiotech & Microbiota Pre- & Probiotics: Market Science, Regulation and Application
Brussels, Belgium Frankfurt, Germany
William Reed Business Media ID&A Ignace Debruyne & Associates VOF
email Jonathan.worsfold@hwgroup.co.uk email info@smartshortcourses.com
web www.amiando.com/probiota web www.smartshortcourses.com

November 7 November 25
10th International Workshop Nutrition & Health Claims Europe: Scientific Research and Health Claims Related to Probiotics:
Effective Clinical Studies for Health Claims Recent Developments
Brussels, Belgium Rome, Italy
Health Claims Europe TV Nutrition Foundation of Italy (NFI)
email info@healthclaims.eu email meeting@nutrition-foundation.it
web www.healthclaims.eu

November 19
Rapid Alert System for Food and Feed (RASFF)
in the European Union
Rome, Italy
Nutrition Foundation of Italy (NFI)
email meeting@nutrition-foundation.it

Exhibitions 2013

October 29–31 November 19–21


Vitafoods Africa Food Ingredients Europe
Johannesburg, South Africa Frankfurt, Germany
web www.vitafoodsafrica.com email Mathias.baur@ubm.com
web www.foodingredientsglobal.com

1 3 Healthcare
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N90

Suppliers Index N90

Natural Extracts NATURAL EXTRACTS

• Bionap p N90
• Naturex p N90

Contract Manufacturing
BIONAP Srl
• Biofarma p N91 Via Badalà, 6 - 95010 S Venerina (CT)
• Labomar p N91 tel +39 095 7086560 - fax +39 095 958435
info@bionap.com - www.bionap.com
• OFI p N91
Founded in 1997, Bionap is an Italian company which produ-
• S.I.I.T. p N91 ces standardized extracts obtained from plants and fruits of
the Mediterranean area, designed for food supplements, fun-
ctional foods and cosmeceutical manufacture. Efficacy and sa-
Natural Ingredients fety of BIONAP extracts are supported by continuous scientific
research and the effectiveness of BIONAP ingredients has
• Gee Lawson p N92
been proved by several experimental and clinical trials, publi-
• Nexira p N92 shed in scientific international journals. Innovative technologies
and our qualified team of experts make BIONAP as serious
and reliable partner.
Ingredients
Our ingredients:
• Sochim p N92 - Red Orange Complex®
- Pantescal®
- Bergavit®
Probiotics - Mucosave®
- Cognigrape®
• UAS p N93
- Morosil®
• Probiotical p N93 - Vitis Biocomplex®
- Skin Moon®
• Sabinsa p N93
- Skin Save®
- Renegrape®
- Opuntia Biocomplex®

NATURAL EXTRACTS

NATUREX SpA
Via Galileo Ferraris 44 - 21042 Caronno Pertusella (VA)
tel +39 02 460 927 - fax +39 02 4817 140
naturex.it@naturex.com - www.naturex.com

Naturex manufactures natural specialty ingredients for the


Food & Beverage, Nutrition & Health and Personal Care indu-
stries. Headquartered in France, Naturex employs over 1400
people and has 15 production units located in Europe
(France, Italy, Spain, Switzerland, Poland and England), United
States (New Jersey and California), Brazil, Australia, Morocco
and India. The group also has several sales offices worldwide.
Nutrafoods 3_Layout 1 18/10/13 11.43 Pagina N91

N91

CONTRACT MANUFACTURING CONTRACT MANUFACTURING

OFI Spa
BIOFARMA Spa
Officina Farmaceutica Italiana
Via Castelliere, 2 - 33036 Mereto di Tomba (UD)
Via A. Verga, 14 - 24127 Bergamo
Tel + 39 0432 868 711 - Fax + 39 0432 868 018
Tel + 39 035 402 929 - Fax + 39 035 403 344
biofarma@biofarma.it - www.biofarma.it
dircom@ofi.it - www.ofilab.com
Biofarma is a Company Specialized in manufacturing on be-
OFI's laboratories develop and supply dietary-nutritional
half of thirds parties of:
products and supplements, paying attention to nutritional
- Food supplements in liquid, solid and powder form (Mini-
conformity and to the search for increasingly new formulas
sterial Authorization nr. 2006/Off.173/82 AG)
of quality.
- Filling in single dose sachets
OFI is specialized in the contract manufacture of a range of
- Class 1, 1a, 2a, 2b, 3 medical devices
dietary-nutritional supplements, in capsule, tablet form and
Possibility of supplying the products in full-service, bulk or drinkable.
packed in various packaging typologies (pillboxes, blister, Certified quality system ISO 9001-ISO 14001
vials, bottles and sachets).
Certification GMP requirements, according to ISO22176 and
FDA 21 CFR Part 111 guidelines. CONTRACT MANUFACTURING
Certification UNI EN USO 9001:2008

CONTRACT MANUFACTURING

S.I.I.T. Srl
info@siit-it.com - www.siitgroup.com
Solid Liquid
LABOMAR Srl Via Canova , 6 Via R. Murri 55/57
Via N. Sauro, 35/d - 31036 Istrana (TV) 20090 Trezzano sul Naviglio (MI) 20013 Magenta (MI)
Tel + 39 0422 73 12 - fax + 39 0422 731 208 tel +39 02 4843 521 tel +39 02 9729 1824
labomar@labomar.com - www.labomar.com fax +39 02 4840 1793 fax +39 02 9728 3044

Labomar is highly skilled in manufacturing food supplements, Solid oral dosage forms:
dietetic foods and medical devices. Products frequently ex- - Pharmaceutical solid form (GMP)
ploit innovative patents, developed by its R&D department - Medical devices solid production (ISO 22000)
"Labomar Research". - Health food supplemets solid production (HACCP)
Extremely flexible production systems allow the creation of Liquid oral dosage forms:
different sizes batches and pilot scale batches. - Health food supplements liquid oral dosage forms
R&D resources’ high expertise allows Labomar to offer a - Medical devices liquid production
complete service in all product development phases.
R&D group is involved in finding out new functional actives
Certifications and Compliances and in setting technological processes allowing to improve
ISO 9001:2008 absorption and bioavailability.
ISO 13485:2012 This effort allowed SIIT to get more than 20 patents in the
GMP Nutritional Supplements last 5 years.
Nutrafoods 3_Layout 1 18/10/13 11.44 Pagina N92

N92

NATURAL INGREDIENTS NATURAL INGREDIENTS

NEXIRA
GEE LAWSON LTD. 129 Chemin de Croisset
HEAD OFFICE 76723 ROUEN France
Melville House, 8-12 Woodhouse Road, Tel : +33 2 32 83 18 18 - Fax :+33 2 32 83 19 19
London N12 0RG, United Kingdom info@nexira.com - www.nexira.com
EUROPEAN OFFICES Nexira is a world leader in the supply of natural ingredients
Lugano, Switzerland - Kaunas, Lithuania - Turin, Italy
and active botanical extracts for food, nutrition and dietary sup-
Helpline +44 (0) 20 8343 5400 - www.geelawson.com plements. Nexira operates on 5 continents with 11 subsidia-
ries, 9 manufacturing plants and an extensive network of
A distributor of active ingredients to the Health Food Supple-
partners in more than 80 countries. Nexira has built its repu-
ment industry. We source raw materials worldwide seeking
tation as the world leader in acacia gum and now offers a wide
the best in terms of quality, legal status with full traceability
range of natural ingredients with recognized health benefits.
to meet your local requirements
Nexira’s portfolio of products includes highly functional and
• Key Raw Materials - actives
nutritional botanical extracts, antioxidants, and a premium
Vitamins, Minerals, Plant Extracts, Organic EU Red Yeast Rice,
range of active ingredients for weight-management, anti-stress,
Marine derived products including Seaweed, Fish Oils, Marine
sport nutrition, fiber enrichment, digestive health and cardio-
Collagen, Chondroitin and Glucosamine, Antioxidants, Natural
vascular health.
Coenzyme Q10, Probiotics, Amino Acids and many other
The three divisions of Nexira - Food, Health & Technology -
speciality ingredients.
offer global expertise from raw material sourcing and proprie-
• Trade Mark Products
tary processing technologies to formulation support.
Include: Ester-C® Calcium Ascorbate-Threonate, OptiMSM®,
With 117 years of experience, the family-owned company con-
Seagreens®, Golden Omega®, Naticol®, Bioenergy® Ribose,
tinues to reinvent and drive the business to new heights of
Orgenetics®, Longvida®, NEM®, Satiereal®, and selected others.
performance with innovative products, customer partnerships
We are ISO 9001:2008 and global supply assurance.

INGREDIENTS • microencapsulated Essential Fatty Acids • Aminoacids • Paten-


ted Hydrolized collagens • Natural Colorants

SOCHIM offers you excellence in the nutritional market with a


world-class of active ingredients for innovative products. 22
corporate brand producers:
• Algea (Norway) • Biocell Technology (USA) • Biosecur Lab.
(Canada) • Cyvex Nutrition (USA) • Ganeden Biotech (USA) •
SOCHIM INTERNATIONAL SpA Isocell Nutra (France) • Jost Chemical Europe (Belgium) • Lyco-
Via Ghisolfa, 86 - 20010 Cornaredo (MI) Italy
red (Israel) • Marinova Pty (Australia) • New Zealand extracts
Ph. +39 02.62020 - fax +39 02.6202040
(New Zealand) • Nexira Health (France) • Nutra Canada (Ca-
sochim@sochim.it - www.sochim.com
nada) • Nutragenesis (USA) • P.L. Thomas (USA) • Pharmachem
Company with a Quality System certified by ISO 9001:2008 Laboratories (USA) • Roxlor Int. (USA) • Sabinsa Corporation
for distribution of raw materials and production of finished pro- (USA) • Soft Gel Technologies (USA) • Shimizu Chemical Cor-
ducts and by ISO 13485:2003 for medical device. poration (Japan) • Taiyo Europe (Germany) • Valensa Interna-
tional (USA) • Waitaki Biosciences (New Zealand)
Raw Materials of Natural Origin for food supplements,
dietary products and cosmetics: In our in-house contract manufacturer site we produce a wide
• Standardized Botanicals extract • Carotenoids pure & microin- range of oral form, tablets, hard shell capsules, softgel capsules,
capsulated • Probiotics • Prebiotics • Fibers and Glucomannan • powders and granulates. Customized packaging in bottles, bli-
Polysaccharides of marine origin • Vitamins of Natural Origin ster, sachet and stick pack, offering a full service from ingre-
pure & microencapsulated • Minerals (gluconate, lactate, citrate) dients to finished products. R&D for finished product.
Nutrafoods 3_Layout 1 18/10/13 11.44 Pagina N93

N93

PROBIOTICS PROBIOTICS

UAS LABORATORIES, INC


The Probiotic Company
6800 France Ave. S.
SABINSA EUROPE GMBH
Suite 520 - Edina, MN 55435
Monzastrasse 4 - 63225 Langen - Germany
Ph (952) 935-1707 - (T) 1-800-422-3371 (DDS1)
tel +49 6103 2701111 - fax +49 6103 2701127
Fax (952)-935-1650
info.europe@sabinsa.com
www.uaslabs.com
Sabinsa Corporation, founded in 1988, supplies high quality
UAS Laboratories, a leading probiotic company, was founded
innovative standardized herbal extracts, phytonutrients, pro-
by Dr. S.K. Dash in 1979. The company manufactures and
biotics, enzymes, spice extracts, minerals, specialty chemicals,
markets premium probiotics with the super strain L. acido-
and fine chemicals for applications in dietary supplements,
philus DDS®-1 in the United States, Canada, and many other
functional foods, pharmaceuticals and cosmetics. Over the
countries worldwide.
past twenty years, Sabinsa has brought to market more than
DDS probiotics have over 200 studies and are used by con-
100 standardized botanical extracts and has obtained several
sumers and recommended by doctors. UAS Laboratories is
IND approved clinical protocols for its products from the FDA.
known for innovation, high technology and premium quality.
With more than 100 scientists working full time conducting
UAS offers finished products, raw materials and private la-
ongoing research both in India and the United States, Sabinsa
beling.
continues to develop and patent beneficial nutrients for the
world market.
Sabinsa’s specialized services include custom product deve-
lopment, technical support and testing lab facilities, assi-
PROBIOTICS stance in clinical evaluation and protocol implementation.
The company also has many recognized trademarked ingre-
dients such as:
- Bacopin®
- BioPerine®
- Boswellin®
- Citrin®
- Cosmoperine®
- Curcumin C3 Complex®
PROBIOTICAL - Curcumin C3 Reduct®
Via E. Mattei 3 -28100 Novara - Italy - DigeZyme®
tel. +39 0321 465933 - fax +39 0321 492693 - Fabenol®
support@probiotical.com
- FenuFibers®
www.probiotical.com
- Fenusterols®
Dedicated to probiotics, Probiotical offers full-cycle expertise - ForsLean®
in research, from isolation to characterization of strains; pro- - Gugulipid®
duction of probiotic cultures; development and realization of - Gymnema Sylvestre GS4®
customized probiotic and synbiotic finished products. Inno- - LactoSpore®
vative and patented process technologies make Probiotical - LactoWise®
a unique presence in its sector able to provide: - Momordicin®
- allergen-free probiotic cultures and finished products tar- - Picroliv®
geted to adults and children with compromised or undefi- - Resvenox®
ned allergy profiles; - Saberry®
- formulations stabilized for up to 24 months at 25°C in va- - Salaretin®
rious dosage forms, included oil suspension and chewable - Selenium SeLECT®
chocolate comfits; - Silbinol®
- microencapsulated probiotic cultures gastric-resistant. - Venocin®.
Nutrafoods 3_Layout 1 18/10/13 11.44 Pagina N94

ADVERTISERS

Page Suppliers Index


Biofarma www.biofarma.it Inside front cover N91
Bionap www.bionap.com IV N90
Food Ingredients Europe www.fi-europe.eu 96
Gee Lawson www.geelawson.com N92
Indena www.indena.com N70
Labomar www.labomar.com N91
Lallemand www.lallemand-health-solutions.com N66
Naturex www.naturex.com N90
Nexira www.nexira.com N69 N92
OFI www.ofilab.com Outside back cover N91
Probiotical www.probiotical.com N93
Sabinsa www.sabinsaeurope.com Inside back cover N93
S.I.I.T. www.siitgroup.com N91
Sochim www.sochim.com N92
Uas Laboratories www.uaslabs.com N93

SUBSCRIBE TO
®

SUBSCRIPTION RATES
For information on subscription rates please contact: Customer Service

The Americas Outside the Americas


(North, South, Central America and the Caribbean)
journals-ny@springer.com subscriptions@springer.com

ORDERS AND INQUIRIES

The Americas Outside the Americas


(North, South, Central America and the Caribbean) via a bookseller or
Springer Journal Fulfillment Springer Distribution Center GmbH
P.O. Box 2485 Haberstrasse 7, 69126 Heidelberg, Germany
Secaucus, NJ 07096-2485, USA Tel.: +49-6221-345-4304
Tel.: 800-SPRINGER (777-4643) Fax: +49-6221-345-4229
Tel.: +1-201-348-4033 (outside US and Canada) e-mail: subscriptions@springer.com
Fax: +1-201-348-4505 Business hours: Monday to Friday 8 a.m. to 8 p.m.
e-mail: journals-ny@springer.com local time and on German public holidays